-0.01 (-0.93%)
Dilution Risk
R&D Expenses
4.55 M
Operating CF
-7.29 M
Total Assets
8.16 M
Total Liabilities
13.29 M
Equity
-5.13 M
D/E Ratio
12,345
Cash Position
5.49 M
Monthly Burn
2.43 M
Runway
0.6 mo
Burn Trend
SEC Filing
May 14, 2026locked
| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Oncolytic Viruses | Oncology | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Oncolytic Viruses | Oncology | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Oncolytic Viruses | Oncology |
Dated clinical, regulatory & corporate events for Oncolytics Biotech Inc.
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REOLYSIN Monoclonal antibody | Carcinoma, Squamous Cell of the Head and Neck | Phase 3 | NCT00753038 | 48% | $1.0B | COMPLETED | 181 | - | - | May 1, 2013 | - | Nov 4, 2014 |
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
pelareorep Fast TrackAcceleratedOrphan | unresectable metastatic squamous cell carcinoma of the anal canal | — | 2026-04-27 | median duration of response of 15.5 months versus 9.5 months; 12-month survival of 82% versus 45.7% Read More | Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study Read More | |
pelareorep Fast TrackAcceleratedOrphan | unresectable metastatic squamous cell carcinoma of the anal canal | — | 2026-04-27 | median duration of response of 15.5 months versus 9.5 months; 12-month survival of 82% versus 45.7% Read More | Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study Read More | |
pelareorep Fast TrackAcceleratedOrphan | unresectable metastatic squamous cell carcinoma of the anal canal | — | 2026-04-27 | median duration of response of 15.5 months versus 9.5 months; 12-month survival of 82% versus 45.7% Read More | Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study Read More |
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Oncolytics Biotech has secured a new U.S. patent protecting the manufacturing process of its investigational immunotherapy, pelareorep, until 2044. This patent enhances the company's intellectual property portfolio and supports the commercial production of pelareorep. Additionally, a method-of-use patent application is under review, potentially extending protection to 2046. Oncolytics plans further patent filings to broaden its intellectual property estate.
Read more →Oncolytics Biotech has appointed Steve Glover to its Board of Directors and promoted John McAdory to Chief Operating Officer. Glover brings extensive experience from his previous role at Ambrx Biopharma, while McAdory will oversee clinical operations and development. The company is focused on advancing its investigational immunotherapy, pelareorep, which shows promise in treating various cancers.
Read more →Oncolytics Biotech has announced positive initial preclinical findings regarding pelareorep, showing enhanced anti-tumor activity when combined with RAS inhibitors. The company plans to continue research on these combinations, particularly in pancreatic ductal adenocarcinoma and colorectal cancer models. CEO Jared Kelly highlighted the potential of pelareorep to improve treatment efficacy against RAS-mutated tumors that are notoriously challenging to treat due to immune resistance. Full results are expected to be released later in 2026.
Read more →Oncolytics Biotech announced that it will present data on pelareorep at the 2026 ASCO Annual Meeting. The data from the GOBLET and AWARE-1 trials indicate that pelareorep enhances immune responses in gastrointestinal tumors. The findings suggest that pelareorep may effectively expand tumor-reactive immune cells, potentially improving treatment options for challenging cancers.
Read more →Oncolytics Biotech has reported promising results for its investigational therapy, pelareorep, in patients with second-line RAS-mutant MSS metastatic colorectal cancer. The therapy demonstrated a median duration of response of 19.5 months, significantly exceeding historical benchmarks. The company is engaging with the FDA to explore an accelerated approval pathway based on these findings.
Read more →Oncolytics Biotech has announced alignment with the FDA on a pivotal clinical study for pelareorep, aimed at treating unresectable metastatic squamous cell carcinoma of the anal canal. The study will focus on patients with no FDA-approved therapies and aims to support both accelerated and full approval. The company plans to incorporate FDA feedback into the final protocol, emphasizing the need for new treatment options in this area.
Read more →Oncolytics Biotech has announced a Type C meeting with the FDA to discuss a registrational pathway for pelareorep in anal cancer. The focus will be on initiating a pivotal study evaluating pelareorep in combination with a checkpoint inhibitor for patients with squamous cell anal carcinoma. Encouraging clinical activity has been observed, with a notable objective response rate in previous studies.
Read more →Oncolytics Biotech has successfully changed its jurisdiction of incorporation from Alberta, Canada, to Nevada, USA. This transition, approved by shareholders, is expected to enhance operational efficiency and access to U.S. capital markets. The company will maintain its Calgary office while establishing a new headquarters in San Diego. The change reflects Oncolytics' status as a U.S. domestic issuer.
Read more →Oncolytics Biotech Inc. announced that two abstracts related to its investigational immunotherapy pelareorep were accepted for presentation at the AACR Annual Meeting 2026. Pelareorep has shown promising results in activating immune responses in various cancers, particularly those driven by RAS mutations. Key data indicate that pelareorep could significantly enhance the effectiveness of immunotherapy and targeted therapies. The company aims to advance its clinical programs to address significant unmet needs in oncology, including pancreatic cancer.
Read more →Oncolytics Biotech has launched a Phase 2 study, REO 033, for metastatic colorectal cancer using pelareorep. The trial will compare the efficacy of pelareorep combined with standard treatments against a control arm. Preliminary data is expected by the end of 2026, following promising results from earlier studies.
Read more →Oncolytics Biotech is advancing its registrational programs in anal and colorectal cancer, with promising data from the GOBLET study. The company plans to meet with the FDA to align on study design for approval. The immuno-oncology market is projected to grow significantly, with Oncolytics positioned to capitalize on this expansion through its innovative therapies.
Read more →Oncolytics Biotech has concluded enrollment in the GOBLET study and will now prioritize registration-focused programs in squamous cell anal cancer and metastatic colorectal cancer. The company believes it has sufficient data to pursue regulatory approval efficiently. A meeting with the FDA is planned for mid-April to discuss the design of a registrational study.
Read more →Oncolytics Biotech has received Fast Track Designation from the FDA for its cancer treatment pelareorep, which demonstrates significant survival benefits in KRAS-mutant colorectal cancer patients. The treatment achieved a 33% response rate and improved median survival to 27 months compared to 11.2 months with standard chemotherapy. The company plans to launch a controlled study to further evaluate pelareorep's efficacy.
Read more →Oncolytics Biotech has received FDA Fast Track Designation for pelareorep in combination with bevacizumab and FOLFIRI for treating KRAS-mutant MSS metastatic colorectal cancer. Clinical data shows a 33% objective response rate and improved survival metrics compared to standard-of-care. The company plans to initiate a controlled study with interim data expected by the end of 2026.
Read more →Oncolytics Biotech announced the results of its Special Meeting of Shareholders, where all proposed resolutions were approved. This includes the company's transition from Alberta to British Columbia and then to Nevada, as well as the implementation of the 2026 Incentive Award Plan. The company anticipates these changes will enhance its operational efficiency and regulatory standing.
Read more →Oncolytics Biotech has appointed John McAdory as EVP of Strategy and Operations and Yujun Wu as VP of Biostatistics. These appointments aim to enhance the company's operational and regulatory capabilities as it advances registration-directed programs in gastrointestinal cancers. McAdory's experience in late-stage oncology trials and Wu's statistical expertise are expected to support Oncolytics' strategic focus on efficient drug development.
Read more →Oncolytics Biotech has announced updated clinical data from GOBLET Cohort 4, showing that the combination of pelareorep and atezolizumab achieved a 29% objective response rate in third-line anal cancer patients. The median duration of response was nearly 17 months, suggesting significant clinical benefit in a heavily pretreated population. The company plans to discuss a registration study with the FDA in early 2026.
Read more →Oncolytics Biotech Inc. plans to change its jurisdiction of incorporation from Alberta, Canada, to Nevada, USA, to better align with its U.S.-focused operations. This move aims to simplify regulatory complexities and enhance access to U.S. capital markets. The proposal is subject to shareholder approval at a special meeting scheduled for January 15, 2026.
Read more →Oncolytics Biotech has provided an update on its intellectual property strategy, focusing on extending patent protection for its immunotherapy drug, pelareorep. The company filed a prioritized examination patent application with the USPTO, which could extend patent claims to 2044. Additionally, Oncolytics plans to file more applications to cover novel uses of pelareorep, aiming to enhance its commercial potential.
Read more →Oncolytics Biotech Inc. released its financial statements for the third quarter of 2025, reporting a significant net loss of $14,400 compared to a loss of $9,543 in the same quarter last year. The company faced a decline in total current assets, which dropped from $18,875 at the end of 2024 to $14,051 as of September 30, 2025. Additionally, the accumulated deficit has increased to $504,965, raising concerns about financial stability and the ability to fund ongoing operations. Despite these challenges, Oncolytics is focused on its clinical development program for its immunotherapeutic agent, pelareorep.
Read more →Oncolytics Biotech reported updated results from its GOBLET study, showing that the combination of pelareorep and atezolizumab achieved a 30% objective response rate in patients with second-line or later squamous cell anal carcinoma. This is more than double the current standard of care's response rate. The median duration of response was 15.5 months, and the company plans to discuss a potential accelerated approval study with the FDA in early 2026.
Read more →Oncolytics Biotech Inc. has filed a registration statement to change its jurisdiction from Alberta, Canada, to Nevada, USA. This move, intended to streamline operations and reduce costs, will be voted on by shareholders at a Special Meeting. If approved, the transition is expected to occur on January 1, 2026. The company will maintain its SEC reporting obligations and continue trading under the ONCY ticker.
Read more →Oncolytics Biotech has announced positive interim results from its GOBLET study, demonstrating strong efficacy signals for its oncolytic virus, pelareorep, combined with atezolizumab in patients with metastatic colorectal cancer. The study has shown a disease control rate of 40% and a 12-month survival rate of 33%. The company is advancing its regulatory strategy focusing on high unmet medical needs and plans to initiate pivotal studies for various indications. With a robust intellectual property portfolio, Oncolytics is well-positioned for future growth in immuno-oncology therapies.
Read more →Oncolytics Biotech announced an update on its planned registration-directed clinical trial for pelareorep in first-line pancreatic ductal adenocarcinoma. The trial aims to evaluate pelareorep in combination with chemotherapy and checkpoint inhibitors, following promising survival data. The company is set to meet with the FDA in mid-November 2025 to discuss the study details.
Read more →Oncolytics Biotech has provided updates on the GOBLET trial, which evaluates pelareorep in gastrointestinal cancers. The trial is expanding to U.S. sites, supported by a grant from PanCAN. Early efficacy data shows promising response rates, with updates on enrollment and efficacy expected in the coming quarters. The company aims to position pelareorep as a foundational immunotherapy for these cancers.
Read more →Oncolytics Biotech has reported strong efficacy data for pelareorep in metastatic colorectal cancer (mCRC), particularly in KRAS mutant patients. The treatment showed significant survival benefits and immune activation in clinical studies. The company plans to advance discussions with regulators and initiate an investigator-sponsored trial to further explore pelareorep's potential in this patient population.
Read more →Oncolytics Biotech has provided updated clinical safety data for pelareorep, demonstrating its favorable safety profile in over 300 gastrointestinal cancer patients. The drug has been administered to more than 1,200 patients and shows potential as a platform therapy. Despite some adverse events, the overall safety data supports its advancement in clinical studies.
Read more →Oncolytics Biotech Inc. will participate in two investor conferences in September 2025. CEO Jared Kelly will meet with institutional investors at the H.C. Wainwright Global Investment Conference and the Lake Street Capital Markets Best Ideas Growth Conference. The company is advancing its immunotherapy, pelareorep, which has shown promise in treating various cancers.
Read more →Oncolytics Biotech announced the results of its Annual General Meeting held on August 8, 2025. All eight proposed nominees were elected as directors, and shareholders approved all resolutions, including fixing the number of directors and appointing auditors. The company continues to develop its immunotherapeutic agent, pelareorep, with promising results in cancer studies.
Read more →Oncolytics Biotech has announced its voluntary delisting from the Toronto Stock Exchange, effective August 22, 2025. The company believes this move is in the best interest of its shareholders, as it will continue to trade on the Nasdaq. Canadian shareholders can still trade shares through U.S. brokers. Oncolytics is focused on developing its immunotherapy, pelareorep, for various cancers.
Read more →Oncolytics Biotech reported its second quarter financial results, highlighting significant advancements in its clinical program for pelareorep, particularly in pancreatic cancer. The company is moving towards a registration-enabling study and has engaged with regulators to finalize the approval pathway. New management aims to optimize development while limiting dilution for shareholders. Despite a reported net loss, the company remains committed to its strategic goals.
Read more →Oncolytics Biotech Inc. released its condensed interim consolidated financial statements for Q2 of 2025, showing a net loss of $6,165, marking a continued decline in financial performance. The accumulated deficit has grown to $490,565, highlighting the financial challenges facing the company as it progresses with clinical trials for its product, pelareorep. Cash and cash equivalents also decreased, and the company anticipates ongoing losses. This financial report raises concerns about the company's capacity to operate without securing additional funding.
Read more →Oncolytics Biotech Inc. announced that its Annual General Meeting will occur virtually on August 8, 2025. Following the formal meeting, CEO Jared Kelly will provide a corporate update, highlighting the company's strategic milestones for the remaining year. Additionally, the second quarter financial results will be disclosed prior to the market opening on the same day. The company continues to develop pelareorep as a promising therapeutic agent in treating various cancers.
Read more →Oncolytics Biotech® has announced plans to engage the FDA for a potential registration-enabled pivotal study in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). The company is optimistic about pelareorep's mechanisms and the positive survival data observed in previous studies. If negotiations with the FDA proceed smoothly, trial activities are expected to start by the end of 2025. Oncolytics sees this as a critical step towards enhancing shareholder value and attracting pharmaceutical partnerships in the field of immunotherapy.
Read more →Oncolytics Biotech hosted a KOL webinar to discuss pelareorep's clinical data for treating pancreatic and gastrointestinal cancers. Key highlights included the significant survival benefits of pelareorep in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients, emphasizing the need for further registration-enabling studies. Panelists noted the potential of pelareorep, particularly in combination with chemotherapy, to address unmet medical needs in cancer treatment. The company remains committed to advancing pelareorep through clinical trials in collaboration with pharma partners.
Read more →Oncolytics Biotech Inc. has received confirmation from Nasdaq that it has regained compliance with the minimum bid price requirements. This follows a period where the company's shares had failed to meet the necessary price, but they have since consistently exceeded the $1.00 bid price for 10 consecutive business days. As a result of this compliance, Oncolytics' shares will continue to trade on the Nasdaq Capital Market under the ticker ONCY. The company is also progressing with trials involving its immunotherapeutic agent, pelareorep, in various cancers.
Read more →Oncolytics Biotech has presented promising aggregated translational data that highlights the efficacy of its treatment pelareorep in turning cold tumors into hot ones, potentially benefiting patients with difficult-to-treat cancers. The data, derived from various clinical studies, underscore the viral replication and immune activation following pelareorep treatment. Generated insights show an increase in PD-L1 expression and T-cell activity, paving the way for future regulatory submissions. The company's commitment to advancing its clinical timeline suggests an optimistic outlook for pelareorep and its potential to meet significant unmet medical needs.
Read more →Oncolytics Biotech Inc. announced that it will host a key opinion leader (KOL) webinar focused on pelareorep, targeting metastatic pancreatic ductal adenocarcinoma and gastrointestinal cancers on July 22, 2025. Esteemed KOLs including Dirk Arnold, Alexander Eggermont, Sanjay Goel, and Devalingam Mahalingam will participate, discussing existing clinical data and potential applications of the immunotherapy. The event will include a formal presentation and a Q&A session with the experts, reflecting Oncolytics' commitment to advancing cancer treatment strategies.
Read more →Oncolytics Biotech Inc. has revealed compelling clinical data on its oncolytic virus therapy, pelareorep, showcasing a significant survival benefit in patients with metastatic pancreatic ductal adenocarcinoma and breast cancer. The company plans to advance pelareorep into registration-enabling trials, emphasizing its strong efficacy signals and favorable safety profile demonstrated across over 1,100 patients. These findings position pelareorep as a potential innovator in immunotherapy, particularly for tumors traditionally considered resistant to such treatments. Additionally, the therapy has received fast-track designations from the FDA, signaling an expedited path toward potential approval.
Read more →Oncolytics Biotech has appointed Andrew Aromando as Chief Business Officer to lead its global business development strategy. Aromando brings extensive experience from Ambrx Biopharma, where he played a key role in a significant acquisition. His primary focus will be to optimize the value of Oncolytics' pelareorep, which shows promise in treating various cancers. The company's CEO expressed confidence in Aromando's ability to enhance clinical and business strategies amid ongoing development efforts.
Read more →Oncolytics Biotech has appointed Jared Kelly as its new CEO to enhance the development of its immunotherapy programs, particularly focusing on pelareorep, which has shown promising clinical results. Kelly's extensive experience in biotech and successful corporate strategies is expected to drive the company's goals of advancing pelareorep's clinical development and securing partnerships. The immunotherapeutic agent has received FDA Fast Track designation for its indications and has demonstrated notable efficacy in recent trials, indicating its potential in oncology treatment.
Read more →Oncolytics Biotech Inc. presented positive clinical trial data regarding pelareorep at the 2025 ASCO Annual Meeting. The Phase I/II GOBLET trial's findings suggest that pelareorep successfully primes the tumor microenvironment, enhancing immune responses and allowing tumor-infiltrating lymphocytes to target pancreatic tumors. The trial demonstrated a 62% overall response rate and highlighted the importance of pre-existing tumor-infiltrating lymphocytes. This data could pave the way for further combination therapies in treating advanced cancers.
Read more →Oncolytics Biotech reported significant advancements in their ongoing clinical trials for pelareorep, particularly in breast, anal, and pancreatic cancers. Their first quarter financial results showed a stable cash position, with $15.3 million available to support further development. The company highlighted promising efficacy data and was recognized for its potential to enhance patient outcomes in difficult-to-treat cancer indications. Upcoming presentations at notable oncology conferences, alongside a substantial share purchase agreement, position Oncolytics for continued growth and innovation in cancer treatment.
Read more →Oncolytics Biotech Inc. reported its financial results for the first quarter of 2025, indicating a net loss of $6,687, which is a slight improvement from the loss of $6,894 in the same quarter the previous year. The company has an accumulated deficit of $484,400, and its total assets decreased to $19,702 compared to $20,187 at the end of 2024. Despite raising $6,228 through a share issuance, there are substantial doubts concerning the company's ability to sustain operations without additional financing. Oncolytics is focused on advancing its cancer treatment, pelareorep, but continues to face challenges in achieving profitability.
Read more →Oncolytics Biotech Inc. (NASDAQ: ONCY) has announced that it will host a conference call and webcast on May 14, 2025, at 4:30 p.m. ET. The call will cover a corporate update and financial results for the first quarter of 2025. The company is focusing on its lead product, pelareorep, which is currently in clinical trials for various cancers, including metastatic breast and pancreatic cancer.
Read more →Oncolytics Biotech Inc. will highlight new data on pelareorep for pancreatic cancer at the upcoming ASCO Annual Meeting. The presentation is based on results from Cohort 1 of the GOBLET study, showcasing pelareorep's potential in improving outcomes for patients with pancreatic ductal adenocarcinoma, a cancer known for its poor treatment options. The study evaluates pelareorep in combination with various therapies and may pave the way for more effective treatments in advanced pancreatic cancer.
Read more →Oncolytics Biotech Inc. has entered into a purchase agreement with Alumni Capital LP, whereby the investor will acquire up to $20 million of the company's common shares. This agreement is seen as a strategic move to enhance the company's financial resources. The execution date for this transaction is set for April 10, 2025, and it outlines the terms for the purchase of securities under specific conditions. The agreement demonstrates confidence in Oncolytics' future potential and market presence.
Read more →Oncolytics Biotech Inc. has entered into a share purchase agreement with Alumni Capital LP, providing up to $20 million in funding to support the clinical development of pelareorep. This funding approach allows Oncolytics to manage the timing and amount of equity sales, thereby minimizing shareholder dilution. Pelareorep, an immunotherapeutic agent, is showing promising results in treating metastatic breast and pancreatic cancers, supporting the company's ongoing clinical trials and advancements towards FDA registrational studies.
Read more →Oncolytics Biotech Inc. (NASDAQ: ONCY) was featured during an H.C. Wainwright event, where key opinion leaders discussed the potential of its immunotherapy, pelareorep, in treating metastatic breast cancer and pancreatic cancer. Dr. Martine Piccart highlighted the necessity for new treatment innovations in HR+/HER2- metastatic breast cancer, while Dr. Alexander Eggermont provided insights into the challenges of pancreatic ductal adenocarcinoma (PDAC) treatment. Pelareorep has shown promise in prior studies, and Oncolytics is planning combination trials as it seeks FDA registrational studies.
Read more →Oncolytics Biotech Inc. reported its financial results for Q4 and year-end 2024, highlighting significant advances in its lead candidate, pelareorep, showing strong efficacy signals across multiple oncology indications. The company surpassed expectations in clinical trials for HR+/HER2- metastatic breast cancer, pancreatic cancer, and anal cancer. While the cash position is $15.9 million, allowing operations through key milestones, the company experienced a significant increase in net loss compared to the previous year, drawing attention to financial health. Management plans to host a conference call to outline future strategies and milestones for 2025.
Read more →Oncolytics Biotech Inc. has announced significant regulatory and clinical advancements for its immunotherapy pelareorep, particularly focusing on pancreatic and anal cancers. The German regulatory authority has approved the continuation of patient enrollment in its pancreatic cancer trial, which signifies a positive safety evaluation. Additionally, new data presented at the ASCO GI 2025 underscores pelareorep's potential efficacy when combined with existing treatment regimens. The company anticipates more data readouts and interactions with regulatory bodies in 2025, which may accelerate clinical trials and registration processes for this innovative therapy.
Read more →Oncolytics Biotech Inc. has made significant advancements in its clinical trials for pelareorep, a potential treatment for pancreatic and anal cancers. The German regulatory agency has approved the continuation of their pancreatic cancer study, and recent data presented at the ASCO GI 2025 conference indicates encouraging efficacy and safety results. With plans to expand enrollment in ongoing trials and favorable interactions with regulators, Oncolytics aims to accelerate progress toward registration-enabling studies for multiple cancers in 2025.
Read more →Oncolytics Biotech Inc. has received a notification letter from Nasdaq indicating that it is not in compliance with the minimum bid price requirement due to its shares closing below $1.00 for 30 consecutive days. The company has until August 12, 2025, to address this deficiency, during which its shares will continue to trade on the Nasdaq. If the company does not meet the requirement, it could face potential delisting, though there are options for additional compliance extensions. The company continues its clinical development of the immunotherapeutic agent pelareorep.
Read more →Oncolytics Biotech has announced that Dr. Matt Coffey will not return to his role as CEO following a medical leave of absence. The decision, made in the interest of his health and family, marks a significant leadership change for the company. Dr. Coffey played a crucial role in the development of the immunotherapeutic agent pelareorep, which has shown promise in Phase 2 clinical studies for metastatic breast and pancreatic cancers. The company is now initiating a search for a new CEO, while Wayne Pisano will serve as Interim CEO during the transition period.
Read more →Oncolytics Biotech presented new data on its immunotherapy pelareorep at the 2025 ASCO Gastrointestinal Cancers Symposium. The therapy showed significant effectiveness over traditional checkpoint inhibitors in anal cancer and maintained a strong safety profile when used with modified FOLFIRINOX in pancreatic cancer. The GOBLET study, which evaluates multiple treatment combinations, continues to provide promising results. The ongoing data collection could further establish pelareorep’s role in treating gastrointestinal tumors.
Read more →Oncolytics Biotech has received regulatory approval from Germany's Paul-Ehrlich-Institute to proceed with full enrollment of 30 patients in a new cohort of its GOBLET study, which investigates the efficacy of pelareorep in treating pancreatic cancer. The approval follows a positive safety review by an independent board, enabling the continuation of testing pelareorep alongside modified FOLFIRINOX. This new cohort aims to assess the impact of the treatment combination on newly diagnosed pancreatic ductal adenocarcinoma patients. Initial efficacy results are expected later this year.
Read more →Oncolytics Biotech has recapped a successful 2024 and projected promising developments for 2025, particularly focusing on breast and gastrointestinal cancer therapies. The results from the BRACELET-1 study have shown significant clinical benefits that potentially lead to registration-enabling studies. Additionally, collaborations in pancreatic cancer and ongoing enrollment in anal cancer studies suggest robust pipeline growth. The company's engagement with the FDA and participation in key conferences are expected to provide further catalysts for advancements in its clinical programs.
Read more →Oncolytics Biotech Inc. announced the acceptance of two abstracts for presentation at the 2025 ASCO Gastrointestinal Cancers Symposium, showcasing promising data on pelareorep's efficacy in pancreatic and anal cancers. The presentations will highlight the drug's ability to enhance immune responses when combined with existing treatments. The results are anticipated to provide insights into pelareorep's potential to improve survival rates in patients with these challenging cancers. The company remains optimistic about advancing clinical trials and securing regulatory pathways for pelareorep.
Read more →Oncolytics Biotech Inc. announced the completion of initial safety phase enrollment of the GOBLET trial, assessing pelareorep combined with modified FOLFIRINOX in pancreatic cancer patients. The Data Safety Monitoring Board recommended continued enrollment after favorable safety data. The trial will be conducted in Germany and could expand to include additional patients, with safety data expected by mid-2025. Oncolytics aims to establish pelareorep as a viable treatment option for patients with newly diagnosed pancreatic ductal adenocarcinoma.
Read more →Oncolytics Biotech reported its financial results for the third quarter of 2024, highlighting successful BRACELET-1 trial data that indicates significant survival benefits for patients with advanced HR+/HER2- breast cancer using pelareorep combined with paclitaxel. The company stated that the positive results warrant a registration-enabling study to further develop pelareorep. Additionally, Oncolytics is focusing on other indications and has managed to maintain a cash position of $19.6 million, expected to sustain operations through 2025 despite experiencing a net loss of $9.5 million for the quarter.
Read more →Oncolytics Biotech Inc. reported its interim financial statements for the third quarter of 2024, revealing a significant accumulated deficit of $469,696. The company's total assets decreased from $38,820 as of December 31, 2023, to $24,262 by the end of September 2024. Notably, total liabilities increased to $15,205, indicating ongoing financial challenges. The company continues to incur substantial losses, including a net loss of $9,543 for the quarter, raising concerns about its ability to sustain operations without additional funding.
Read more →Oncolytics Biotech Inc. will host a conference call on November 12, 2024, at 8:30 a.m. ET to discuss its third quarter financial results and recent operational highlights. The company, focused on developing pelareorep, an immunotherapeutic agent, has shown promising results in clinical studies involving metastatic breast and pancreatic cancers. This call offers stakeholders insight into the company's progress and future plans.
Read more →Oncolytics Biotech has reported significant progress in its clinical studies for breast and pancreatic cancer treatments with pelareorep. The recent BRACELET-1 trial results for HR+/HER2- breast cancer have established a path towards FDA accelerated approval. A large Phase 2 study is planned for early 2025 to support this initiative. Additionally, there are collaborative efforts to explore pelareorep in pancreatic cancer, with ongoing and anticipated studies that aim to further validate its efficacy across various indications.
Read more →Oncolytics Biotech has reported positive results from its BRACELET-1 Phase 2 study, which evaluated the efficacy of pelareorep in patients with advanced HR+/HER2- breast cancer. The study showed that the median overall survival for patients receiving pelareorep in combination with chemotherapy was not reached, with a significant portion of patients still alive at the study's conclusion. The two-year survival rate for pelareorep-treated patients was 64%, nearly double that of the control arm. Based on these encouraging results, Oncolytics is seeking funding for a registration-enabling study to further evaluate pelareorep's clinical potential.
Read more →Oncolytics Biotech Inc. announced that its Chief Financial Officer and Chief Medical Officer will participate in fireside chats at two upcoming investment conferences in September. The conferences include the H.C. Wainwright 26th Annual Global Investment Conference and the 2024 Cantor Global Healthcare Conference, where they will also hold one-on-one investor meetings. The company's investigational agent, pelareorep, has shown promising results in treating certain cancers.
Read more →Oncolytics Biotech Inc. recently announced that its Chief Medical Officer, Dr. Thomas Heineman, will participate in a fireside chat at Canaccord Genuity's 44th Annual Growth Conference, scheduled for August 13-15, 2024, in Boston. In addition to the chat, company management will hold one-on-one meetings with investors at the conference. The company is advancing pelareorep, an immunotherapeutic agent that has shown promising results in clinical trials for breast and pancreatic cancers. Pelareorep is currently being evaluated in combination trials and has received FDA Fast Track designation for its applications in these cancer types.
Read more →Oncolytics Biotech Inc. has entered into a US$50 million equity distribution agreement with Cantor Fitzgerald & Co. This agreement allows Oncolytics to issue and sell common shares through CF&Co as a sales agent, enabling the company to raise capital for ongoing and future initiatives. The placement is subject to compliance with Canadian and U.S. securities regulations, ensuring proper oversight of the sales process. This equity distribution represents a strategic move to enhance the company's financial resources.
Read more →Oncolytics Biotech reported its Q2 2024 financial results, highlighting key operational advances. The company received supportive FDA feedback for its registration-enabling trial of pelareorep in HR+/HER2- metastatic breast cancer and initiated the GOBLET study for pancreatic cancer. Oncolytics also has financial stability with $24.9 million in cash, while reporting a slight decrease in net losses compared to the previous year. Upcoming milestones include overall survival results from the BRACELET-1 study scheduled for the second half of 2024.
Read more →Oncolytics Biotech Inc. will hold a conference call and webcast on August 1, 2024, to discuss its second quarter financial results and corporate updates. The company is focused on immunotherapy with its lead compound, pelareorep, which has shown promising results in cancer studies. With ongoing clinical trials and FDA Fast Track designations, Oncolytics aims to advance its offerings in metastatic breast cancer and pancreatic cancer.
Read more →Oncolytics Biotech has announced positive feedback from a Type C meeting with the FDA regarding its registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer. The trial will focus on progression-free survival as the primary endpoint. The company plans to report overall survival data from the BRACELET-1 trial later this year. This advancement represents a significant step towards providing a new treatment option for patients who have not responded to existing therapies.
Read more →Oncolytics Biotech has announced that Dr. Matt Coffey, the President and CEO, is taking a medical leave of absence, with Wayne Pisano assuming the role of interim CEO. Despite this leadership change, the company expresses confidence in its executive team to continue progress on their strategic goals, particularly regarding the immunotherapeutic agent pelareorep for breast and pancreatic cancers. Upcoming survival data from a key breast cancer study is anticipated in the second half of 2024, while pelareorep is moving closer to registration-enabling studies.
Read more →Oncolytics Biotech Inc. has initiated dosing for the first patient in its GOBLET study, which evaluates the combination of pelareorep and modified FOLFIRINOX in patients with metastatic pancreatic cancer. This study aims to assess safety and efficacy, supported by a US$5 million Therapeutic Accelerator Award from PanCAN. The previous success of pelareorep with chemotherapy raises hopes for a new treatment option, potentially leading to two registration programs for pancreatic cancer interventions. The trial is part of a broader effort to explore pelareorep's applications in various malignancies.
Read more →Oncolytics Biotech presented two abstracts at the 2024 ASCO Annual Meeting, highlighting the potential of pelareorep in treating metastatic pancreatic ductal adenocarcinoma. One abstract discusses a new cohort of the GOBLET study designed to assess pelareorep combined with modified FOLFIRINOX and atezolizumab. The other abstract emphasizes pelareorep's capability to induce tumor-infiltrating lymphocyte expansion, supporting its use as an effective immunotherapy across various cancers. Enrollment for the GOBLET cohort is expected to begin shortly, funded by a $5 million grant from the Pancreatic Cancer Action Network.
Read more →Oncolytics Biotech Inc. has announced a preliminary collaboration with the Global Coalition for Adaptive Research (GCAR) for evaluating pelareorep in a master protocol aimed at treating metastatic pancreatic ductal adenocarcinoma. This initiative seeks to finalize a seamless Phase 2/3 trial design that will study multiple therapies, aiming for expedited data that could support regulatory approval. The collaboration is viewed positively by the leadership of both organizations, who are optimistic about the insights from previous success rates and hope to drive quicker advancements in treatment for pancreatic cancer.
Read more →Oncolytics Biotech has received regulatory clearance to begin a new cohort in its GOBLET study, evaluating the combination of pelareorep with modified FOLFIRINOX and possibly the PD-L1 inhibitor atezolizumab in patients with pancreatic cancer. The initiative is supported by a US$5 million grant from the Pancreatic Cancer Action Network, which aims to enhance treatment options for pancreatic ductal adenocarcinoma. The enrollment of the first patient is anticipated in the second quarter of 2024, marking a significant advancement in Oncolytics' pancreatic cancer program.
Read more →Oncolytics Biotech reported its Q1 2024 financial results, highlighting significant advancements in its clinical trials. The company has been granted a Type C meeting with the FDA to discuss a registration-enabling study for pelareorep in HR+/HER2- metastatic breast cancer. Positive interim results from the GOBLET study have prompted further patient enrollment in the anal cancer cohort, while also initiating a new pancreatic cancer cohort supported by a $5 million grant from PanCAN. The company's cash reserves of $29.6 million provide a solid foundation for continued research and development efforts.
Read more →Oncolytics Biotech Inc. reported its condensed interim consolidated financial statements for the quarter ending March 31, 2024. The company faced a net loss of $6,894 thousand, compared to $6,437 thousand for the same quarter in the previous year, contributing to an accumulated deficit of $452,897 thousand. Despite a mild increase in cash and cash equivalents, the operational losses raise concerns about continued financing. The firm plans to pursue funding through various equity arrangements and strategic collaborations to support ongoing clinical trials.
Read more →Oncolytics Biotech Inc. will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on May 15, 2024, in New York. Dr. Matt Coffey, the company's CEO, will represent Oncolytics during the event. The company is also conducting one-on-one investor meetings at the conference, indicating an active interest in engaging with investors. Pelareorep, Oncolytics' immunotherapeutic agent, continues to show promising results in clinical trials for metastatic breast and pancreatic cancers.
Read more →Oncolytics Biotech Inc. announced the acceptance of two abstracts for the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The abstracts highlight the results of studies involving pelareorep in combination therapies for metastatic cancers, including pancreatic and breast cancer. These presentations could influence future clinical practices and bolster the company's position in the oncology field. Furthermore, pelareorep has shown potential synergies with other oncology treatments and has received Fast Track designation from the FDA for its ongoing studies.
Read more →Oncolytics Biotech has submitted a Type C meeting request to the FDA for pelareorep, aimed at discussing a registration-enabling trial for HR+/HER2- metastatic breast cancer. The company anticipates overall survival results from the BRACELET-1 trial in the second half of 2024. Results from previous trials show promising responses to pelareorep combined with paclitaxel, indicating potential for enhanced clinical outcomes in breast cancer patients. The meeting with the FDA is a significant step toward further development and regulatory approval of this investigational therapy.
Read more →Oncolytics Biotech Inc. announced that CEO Dr. Matt Coffey will participate in the Viral Approaches in Oncology panel at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024. The company is advancing its immunotherapeutic agent, pelareorep, which has shown promising results in Phase 2 studies involving breast and pancreatic cancers. The agent is noted for its ability to enhance anti-cancer immune responses. Additionally, Oncolytics is engaged in virtual investor meetings during the conference to foster investment opportunities.
Read more →Oncolytics Biotech reported positive operational highlights and financial results for Q4 and full year 2023, showcasing the advancement of their lead candidate, pelareorep. The company is set to enter a registration-enabling study for pelareorep in pancreatic cancer and plans to report overall survival data from its BRACELET-1 study in 2024. Improvement in response rates for patients in the GOBLET study led to enrollment expansions, while recent data affirmed pelareorep's immunotherapeutic potential. Despite these advancements, the company reported a net loss of $3.9 million for Q4 2023, although this was a decrease from the previous year.
Read more →Oncolytics Biotech has submitted an amendment to its GOBLET trial to initiate a new Phase 1/2 cohort focusing on pelareorep in combination with modified FOLFIRINOX for newly diagnosed metastatic pancreatic patients. This study is backed by a $5 million grant from the Pancreatic Cancer Action Network and aims to evaluate the efficacy of this combination treatment. The prior cohort reported promising results, with a significant objective response rate, indicating potential advancements in treatment options for pancreatic cancer. Pending approval from Germany's regulatory body, patient enrollment is anticipated to commence soon.
Read more →Oncolytics Biotech Inc. will host a conference call on March 7, 2024, at 4:30 p.m. ET to discuss its fourth quarter and full year financial results, along with recent operational highlights. The company is focused on developing pelareorep, an immunotherapeutic agent, which has shown promise in treating various cancers. With Fast Track designation from the FDA for its studies on metastatic breast and pancreatic cancers, Oncolytics is planning further combination clinical trials.
Read more →Oncolytics Biotech Inc. will be represented by CEO Dr. Matt Coffey at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference, which runs from February 29 to March 2, 2024. During the conference, management will engage in one-on-one investor meetings and a live webcast of the presentation will be available on the company's website. The company is developing pelareorep, an immunotherapeutic agent that has shown promise in breast and pancreatic cancers and is advancing towards registrational studies.
Read more →Oncolytics Biotech Inc. announced an expansion of enrollment for the anal cancer cohort in the GOBLET study, following positive Stage 1 results. The study evaluates pelareorep combined with atezolizumab in patients with second-line unresectable squamous cell carcinoma of the anal canal. The initial results presented at IMACC 2023 showed a 37.5% objective response rate, including a complete response, representing a significant advancement over existing treatments. This expansion aims to solidify findings for potential regulatory pathways and improved options for patients with advanced anal cancer.
Read more →Oncolytics Biotech has appointed Patricia S. Andrews to its Board of Directors, enhancing its leadership with her extensive experience in oncology. Andrews has a successful track record in clinical trials and business development, particularly relevant as Oncolytics prepares for pivotal studies with its drug pelareorep. The company’s recent studies have shown promising results in breast and pancreatic cancers, indicating potential advancements in cancer care as they move forward with their clinical and corporate development plans.
Read more →Oncolytics Biotech reported significant achievements for 2023, primarily driven by promising clinical results for its immunotherapeutic agent, pelareorep. The company plans to initiate multiple Phase 3 studies in 2024, including a pivotal trial for pancreatic cancer and a study targeting metastatic breast cancer. With a current cash position of $40 million and positive feedback from regulators, Oncolytics aims to enhance its development programs and engage potential partners. Key milestones for the upcoming year include guidance on registration for metastatic breast cancer and adaptive Phase 3 trials for pancreatic cancer.
Read more →Oncolytics Biotech presented new translational data on pelareorep at the San Antonio Breast Cancer Symposium (SABCS). The results from the AWARE-1 study showed an expansion of tumor-infiltrating lymphocytes (TILs) which correlates with decreased tumor size, indicating pelareorep's promising role as an immunotherapy. The study also suggested that these findings would inform future registrational studies in metastatic breast cancer and pancreatic cancer. The data reinforces pelareorep's capacity to enhance T cell infiltration and supports its development in combination therapies.
Read more →Oncolytics Biotech has announced that the anal cancer cohort of its Phase 1/2 GOBLET study has met the predefined success criteria for efficacy. The combination treatment of pelareorep and atezolizumab demonstrated a 37.5% objective response rate, including one complete response. The data were presented at the International Multidisciplinary Anal Cancer Conference 2023, indicating promising potential for treating unresectable squamous cell carcinoma of the anal canal. The study's findings further support the development of pelareorep as a viable option in gastrointestinal cancers.
Read more →Oncolytics Biotech has provided an update on its pancreatic cancer program for pelareorep, announcing an adaptive Phase 3 strategy following PanCAN's reevaluation of the Precision Promise program. They confirmed the receipt of a $5 million Therapeutic Accelerator Award from PanCAN to support the GOBLET study arm combining pelareorep with modified FOLFIRINOX. The Phase 3 program aims to start enrolling patients by mid-2024, leveraging a strong Phase 2 dataset and collaborations within the pancreatic cancer community.
Read more →Oncolytics Biotech Inc. has presented additional positive translational data from the AWARE-1 breast cancer study at the SITC annual meeting. The presentation highlights pelareorep's role in increasing PD-L1 positive cells and T cell infiltration within the tumor microenvironment. This data is expected to support the development of a registrational program for pelareorep in HR+/HER2- metastatic breast cancer. The findings also suggest potential implications for other cancer types treated with pelareorep in combination with atezolizumab.
Read more →Oncolytics Biotech reported robust third-quarter results, emphasizing the success of its pelareorep in pancreatic cancer trials. The company demonstrated significant improvements in survival data over historical control groups and secured a $5 million grant from PanCAN to support further studies. Financially, Oncolytics ended the quarter with $40 million in cash, ensuring operational funding through upcoming critical milestones. Despite these positives, the company reported an increased net loss and higher operational expenses compared to the previous year, indicating ongoing financial challenges.
Read more →Oncolytics Biotech has presented updated results from its Phase 1/2 GOBLET study at the ESMO 2023 meeting in Madrid, reporting favorable outcomes for its pelareorep-based therapy in pancreatic ductal adenocarcinoma (PDAC). Key findings include a median progression-free survival of 7.2 months and an interim median overall survival of 10.6 months, both significantly surpassing historical benchmarks. The study demonstrated a 62% objective response rate and an 85% disease control rate, while also showing T-cell expansion associated with treatment response. The company plans to advance to Phase 3 trials in this indication.
Read more →Oncolytics Biotech Inc. announced interim results from the Phase 1/2 GOBLET study, which evaluated the efficacy of the treatment combination of pelareorep, atezolizumab, and trifluridine/tipiracil in patients with third-line metastatic colorectal cancer. The study achieved its success criteria, showing a 40% overall disease control rate, with four out of fourteen patients demonstrating stable disease at week 16. These findings support pelareorep's potential as a backbone immunotherapy in combination with atezolizumab, providing promising data on its mechanism of action and clinical benefits for patients who have undergone multiple prior treatments.
Read more →Oncolytics Biotech announced it will present two posters at ESMO 2023, detailing findings from the GOBLET study on pelareorep, a novel immunotherapy. Preliminary data reveals an 82% overall survival rate at six months for advanced pancreatic ductal adenocarcinoma patients treated with pelareorep in combination with atezolizumab and chemotherapy. Additionally, interim results for metastatic colorectal cancer patients indicate a clinical benefit rate of 33%. These findings mark a significant advancement in the treatment of these cancers and support the ongoing development of pelareorep.
Read more →Oncolytics Biotech, Inc. has been awarded a $5 million grant from the Pancreatic Cancer Action Network (PanCAN) to further develop its investigational immunotherapy, pelareorep, for pancreatic cancer. This funding will facilitate clinical trials exploring the combination of pelareorep with modified FOLFIRINOX chemotherapy. The initiative aims to provide new treatment options for pancreatic cancer patients, a disease known for its aggressive nature and high mortality rates. Following the FDA's Fast Track designation of their treatment combination, Oncolytics seeks to improve patient outcomes through innovative therapy approaches.
Read more →Oncolytics Biotech Inc. announced its participation in the Cantor Global Healthcare Conference 2023, scheduled for September 26-28, where CEO Dr. Matt Coffey will participate in a fireside chat. The company will also engage in one-on-one investor meetings at the conference. A live webcast of the presentation will be accessible on Oncolytics' website, with content archived for three months. The company continues to develop its immunotherapeutic agent, pelareorep, which has shown promising results in cancer treatment.
Read more →Oncolytics Biotech Inc. announced the full exercise of the over-allotment option from their public offering, raising an additional $2,250,112. This was part of a larger offering totaling $15,000,750 aimed at advancing the company's pelareorep clinical programs targeting metastatic breast and pancreatic cancers. The offering is supported by a prospectus filed in multiple Canadian jurisdictions. The underwriter received a commission and compensation warrants as part of the transaction.
Read more →Oncolytics Biotech Inc. announced that CEO Dr. Matt Coffey will speak at the H.C. Wainwright 25th Annual Global Investment Conference taking place from September 11-13, 2023, in New York. The company will also participate in one-on-one investor meetings and provide a live webcast of the presentation. Oncolytics is known for developing pelareorep, an immunotherapeutic agent aimed at treating various cancers. This event is expected to increase the company's engagement with potential investors.
Read more →Oncolytics Biotech reported positive results for the second quarter of 2023, highlighting advancements in their clinical programs for breast and pancreatic cancers. A phase 2 trial demonstrated robust improvements in response rates and survival metrics for HR+/HER2- metastatic breast cancer, and pelareorep was selected for participation in the Precision Promise phase 3 trial aimed at pancreatic cancer. The company also enhanced its financial stability through a public offering, increasing its cash reserves to potentially support its operational and clinical objectives into 2024. However, the company reported an increased net loss compared to the same quarter in the previous year.
Read more →Oncolytics Biotech has successfully closed a public offering of US$15 million aimed at advancing its clinical programs for pelareorep in metastatic breast and pancreatic cancers. The offering consisted of 6,667,000 units at a price of US$2.25 per unit, and included participation from a significant institutional investor. Proceeds from the offering will be used for clinical development as well as corporate purposes. The company continues to make progress with pelareorep, which has shown promising results in ongoing and planned combination therapies.
Read more →Oncolytics Biotech has announced a US$15 million bought deal offering of Equity Units, consisting of common shares and warrants, underwritten by Leede Jones Gable Inc. The funds raised will be used to further clinical programs for its immunotherapeutic agent, pelareorep, particularly in metastatic breast and pancreatic cancers. The anticipated closing date for this transaction is around August 4, 2023, subject to regulatory approvals. This move represents a strategic effort to enhance the company's financial position and develop its cancer therapies.
Read more →Oncolytics Biotech's pelareorep has been chosen for inclusion in the Precision Promise adaptive Phase 3 clinical trial aimed at treating first-line metastatic pancreatic ductal adenocarcinoma. This innovative trial design will reduce the cost and time required for registration by nearly 50%. Previous data has shown a significant improvement in response rates when pelareorep is combined with standard treatment options. The company aims to finalize its agreements and commence the trial in early 2024, providing hope for pancreatic cancer patients facing limited treatment options.
Read more →Oncolytics Biotech announced promising updated results from its BRACELET-1 randomized phase 2 trial targeting HR+/HER2- metastatic breast cancer. The trial showed a significant reduction in disease progression risk by 71% and an overall response rate of 37.5% when combining the drug pelareorep with paclitaxel. Additionally, a 12-month progression-free survival rate of 32.8% was reported for the combination treatment. These results position Oncolytics to advance towards a pivotal phase 3 registrational study.
Read more →Oncolytics Biotech Inc. will host a key opinion leader webinar on June 5, 2023, to discuss the BRACELET-1 trial results in HR+/HER2- metastatic breast cancer. The webinar will include insights from renowned experts such as Richard Vile, Aleix Prat, and Martine J. Piccart, focusing on the current treatment landscape and the implications of the trial data. Pelareorep, an immunotherapeutic agent, has shown potential in eliciting immune responses against cancer, highlighting Oncolytics' ongoing efforts in cancer research.
Read more →Oncolytics Biotech announced positive results from its BRACELET-1 trial, which evaluated the efficacy of pelareorep combined with paclitaxel in treating HR+/HER2- metastatic breast cancer. The study showed a 31.3% overall response rate and 9.6-month median progression-free survival for the combination therapy compared to 20% and 6.4 months of survival for paclitaxel alone. These findings support the drug's progression to phase 3 registrational studies, marking a significant step in the development of new treatments for this patient population. Further updated data from the trial will be presented at the ASCO Annual Meeting in June 2023.
Read more →Oncolytics Biotech reported its financial results for Q1 2023, highlighting operational progress and upcoming milestones related to its cancer therapies. The company will showcase data from the BRACELET-1 trial at the ASCO Annual Meeting, which is anticipated to inform future registrational studies. Management expressed confidence in their programs targeting HR+/HER2- metastatic breast cancer and first-line pancreatic cancer, along with an optimistic cash position for ongoing development. Overall, recent results underscore the promise of pelareorep in treating significant cancer indications.
Read more →Oncolytics Biotech Inc. announced that its abstract detailing the BRACELET-1 trial will be presented orally at the ASCO Annual Meeting on June 3, 2023. The trial focuses on combining the oncolytic reovirus pelareorep with chemotherapy and immunotherapy for HR+/HER2- metastatic breast cancer. CEO Dr. Matt Coffey expressed pride in this opportunity, emphasizing its importance to stakeholders in breast cancer treatment. The data published at ASCO aims to contribute to advancements in this critical area of oncology.
Read more →Oncolytics Biotech Inc. has announced the details for its upcoming annual general meeting, scheduled for May 9, 2023. Shareholders will have the opportunity to vote on director nominees and proposals through a virtual format. The company is actively mailing voting materials and encourages shareholders to participate prior to the voting deadline on May 5, 2023. Alongside logistical details, Oncolytics also highlights its ongoing development of pelareorep, an immunotherapeutic agent aimed at enhancing immune responses in cancer treatment.
Read more →Oncolytics Biotech Inc. has announced that its CEO, Dr. Matt Coffey, will participate in a panel presentation titled 'Novel Mechanisms with Important Readouts' at Cantor Fitzgerald's Future of Oncology Virtual Symposium scheduled for April 3-5, 2023. This participation signifies the company's active role in discussions regarding new cancer treatment mechanisms. Additionally, Oncolytics plans to engage in virtual one-on-one investor meetings during the event.
Read more →Oncolytics Biotech reported its fourth quarter and full year 2022 financial results, highlighting significant advances in its cancer programs. The company is moving towards registration for its pancreatic cancer treatment following impressive results from the phase 1/2 GOBLET trial. Additionally, the phase 2 BRACELET-1 trial for metastatic breast cancer is set for a key data readout in Q2 2023, supported by FDA Fast Track designations. However, despite positive developments, the company reported a net loss of $8.6 million for the fourth quarter.
Read more →FDA Fast Track designation granted after presentation at the SITC 37th Annual Meeting demonstrating 69% objective response rate SAN DIEGO, and CALGARY, AB, Dec. 1, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the U.S. Food and Drug
Read more →SAN DIEGO and CALGARY, AB, Nov. 21, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of two abstracts for poster presentations at the upcoming San Antonio Breast Cancer Symposium (SABCS), to be held at the Henry B. González C
Read more →One complete response (CR) and eight partial responses (PR) achieved in thirteen evaluable patients 69% objective response rate (ORR) is nearly three times greater than the average ORR of ~25% reported in historical control trials Data support Oncolytics' plan to advance its pa
Read more →Condensed Interim Consolidated Financial Statements Oncolytics Biotech Inc. September 30, 2022 and 2021 ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (in Canadian dollars, except share amounts) As at September 30, 2022 December 31,
Read more →Clinical interim data reported earlier today from GOBLET trial's pancreatic cancer cohort show an objective response rate (ORR) nearly triple the average ORR seen in relevant historical control trials Pipeline now provides multiple registration opportunities in breast and pancre
Read more →70% objective response rate (ORR; n=10) is nearly triple the average ORR of ~25% reported in historical control trials1-4 Data suggest pelareorep synergizes with PD-(L)1 inhibitors and standard-of-care chemotherapy in advanced/metastatic pancreatic ductal adenocarcinoma Oncolyt
Read more →Interim results from the phase 1/2 GOBLET study's pancreatic cancer cohort to be presented in a poster on November 11th and discussed during a key opinion leader webinar on November 14th at 10 a.m. ET SAN DIEGO, and CALGARY, AB, Oct. 5, 2022 /PRNewswire/ -- Oncolytics Biotech® I
Read more →Mr. Rigby is the Group Chief Executive Officer of Revolo Biotherapeutics and has three decades of experience in the pharmaceutical and biotechnology industries SAN DIEGO and CALGARY, AB, Sept. 7, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today annou
Read more →Condensed Interim Consolidated Financial Statements Oncolytics Biotech Inc. June 30, 2022 and 2021 ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (in Canadian dollars, except share amounts) As at June 30, 2022 December 31, 2021 Asse
Read more →Phase 2 BRACELET-1 trial fully enrolled and advancing towards a randomized data readout that is expected to inform the design of a registrational study in HR+/HER2- breast cancer Achieved success criteria for efficacy in Stage 1 of the GOBLET trial's pancreatic cancer cohort wit
Read more →Partial responses achieved in all patients in cohort's 1b portion Expansion criteria for pancreatic cancer cohort has been met to allow for additional patient enrollment Data suggest pelareorep synergistically combines with chemotherapy and checkpoint inhibition in a highly cha
Read more →Canaccord Genuity LLC 99 High Street, 12th Floor Boston, Massachusetts 02110 Ladies and Gentlemen: Oncolytics Biotech Inc., a company incorporated under the Business Corporations Act (Alberta) (the "Company"), confirms its agreement (this "Agreement") with Canaccord Genuity
Read more →Mr. Parsons served as the Chief Financial Officer of Trillium Therapeutics, which was recently acquired by Pfizer Inc. SAN DIEGO and CALGARY, AB, June 17, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the voting results from its Annual
Read more →SAN DIEGO, Calif. and CALGARY, AB, May 10, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, President and Chief Executive Officer, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Co
Read more →Condensed Interim Consolidated Financial Statements Oncolytics Biotech Inc. March 31, 2022 and 2021 ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (in Canadian dollars, except share amounts) As at March 31, 2022 December 31, 2021 As
Read more →Anticipated Q4 2022 data readout from randomized phase 2 study in breast cancer is on track and expected to inform the design of a registrational trial Clinical biomarker data demonstrates pelareorep's induced improvement in the prognosis of HR+/HER2- breast cancer patients by d
Read more →Pelareorep treatment resulted in a favorable Risk of Recurrence Score (ROR-S) in 100% of evaluable patients compared to 55% at baseline in a window-of-opportunity study Statistically significant increases in markers of tumor cell death and T cell activation observed following tr
Read more →SAN DIEGO, Calif. and CALGARY, AB, May 2, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) and SOLTI-Innovative Cancer Research today announced the acceptance of an abstract for a poster presentation at the upcoming European Society for Medical Oncology Bre
Read more →SAN DIEGO, Calif. and CALGARY, AB, April 21, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, President and Chief Executive Officer, will be presenting a corporate overview at the Bloom Burton & Co. Healthcare Investor
Read more →- Pelareorep-CAR T combination may expand the commercial potential of CAR T cells to solid tumors - Combining CAR T cells with pelareorep prevented antigen escape by creating CAR T cells with dual specificity through a novel mechanism - Loading CAR T cells with pelareorep led t
Read more →SAN DIEGO, Calif. and CALGARY, AB, April 12, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Thomas Heineman, M.D., Ph.D., the Company's Chief Medical Officer, will be participating in a fireside chat at the Canaccord Genuity Horizons
Read more →- Pelareorep's immunotherapeutic effects produced progression-free survival of >3 years in a subset of multiple myeloma patients who had failed prior therapy - Results strengthen the clinical dataset demonstrating pelareorep's ability to remodel the tumor microenvironment SAN D
Read more →- Results demonstrate meaningful and durable efficacy signal in a highly challenging indication - A higher dose level of pelareorep led to 50% 24-month median overall survival (mOS) and a patient still alive at 42 months compared to 16.7% mOS at the lower dose - Investigator-sp
Read more →SAN DIEGO, Calif. and CALGARY, AB, April 6, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is providing a letter to shareholders, included below. To Oncolytics' Shareholders, During the first quarter of 2022, we continued to make important progress acro
Read more →Independent review identified, no safety concerns in trial's final safety run-in Cohort supported by prior clinical data showing a pelareorep-based combination driving a 90% clinical benefit rate in KRAS-mutated colorectal cancer patients Multi-indication trial being conducted
Read more →First two cohorts indicate pelareorep in combination with paclitaxel was well-tolerated with no new safety signals observed to date Trial is designed to satisfy regulatory requirements and accelerate pelareorep's development in large and rapidly growing pharmaceutical markets, i
Read more →SAN DIEGO and CALGARY, AB, March 17, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of preclinical and patient data on pelareorep in the peer-reviewed journal Immunology. The paper, entitled "Oncolytic virus treatment diffe
Read more →SAN DIEGO, Calif. and CALGARY, AB, March 9, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced an upcoming poster presentation that will feature long-term follow-up results from ReoGlio, an investigator-sponsored, phase 1b trial evaluating the
Read more →- Prolonged progression-free survival of >3 years achieved in a subset of relapsed/refractory patients - Treatment-induced increases in tumor-infiltrating anti-cancer immune cells correlated with clinical response SAN DIEGO, Calif. and CALGARY, AB, March 9, 2022 /PRNewswire/ --
Read more →Randomized phase 2 metastatic breast cancer trial (BRACELET-1) on track for top-line data in Q4 2022 Clinical breast cancer data indicate pelareorep-induced changes in blood T cell populations may be a predictive biomarker – a key finding for de-risking a phase 3 registrational
Read more →Independent safety review completed with no toxicity concerns Cohort builds on prior proof-of-concept data demonstrating clinical benefit of pelareorep-checkpoint inhibitor combination in pancreatic cancer Multi-indication trial being conducted in collaboration with Roche and A
Read more →Enrollment in the first dose escalation is complete with no safety issues reported to date Trial is designed to accelerate pelareorep's development in Asian territories such as China, the world's second-largest pharmaceutical market SAN DIEGO, Calif. and CALGARY, AB, Jan. 27, 2
Read more →SAN DIEGO, Calif. and CALGARY, Canada, Jan. 20, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) provided an enrollment update on the phase 1/2 GOBLET study in a poster presentation at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers
Read more →SAN DIEGO, Calif. and CALGARY, AB, Jan. 11, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is providing a letter to shareholders, included below. To the Shareholders of Oncolytics Biotech, 2021 generated ground-breaking data that creates the foundation
Read more →- Dr. Heineman has over two decades of experience successfully leading clinical development programs and previously served as Oncolytics' Global Head of Clinical Development and Operations SAN DIEGO and CALGARY, AB, Dec. 21, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:
Read more →- Treatment with intravenous pelareorep plus azacitidine reduced tumor burden - Treatment with pelareorep and azacitidine dramatically upregulated multiple genes known to drive anti-cancer immune responses SAN DIEGO and CALGARY, AB, Dec. 15, 2021 /PRNewswire/ -- Oncolytics Biot
Read more →- No safety concerns have been noted in any trial participants - Trial builds on prior clinical data demonstrating pelareorep's ability to reverse immunosuppressive tumor microenvironments and upregulate PD-L1 expression in breast cancer SAN DIEGO, Calif. and CALGARY, AB, Dec.
Read more →IRENE study is evaluating pelareorep-anti-PD-1 combination treatment in metastatic TNBC SAN DIEGO and CALGARY, AB, Nov. 19, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will present an update on the Phase 2 IRENE trial
Read more →Interim Consolidated Financial Statements Oncolytics Biotech Inc. September 30, 2021 and 2020 ONCOLYTICS BIOTECH INC. INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (in Canadian dollars, except share amounts) As at September 30, 2021 December 31, 2020 Assets Curr
Read more →Clinical breast cancer data indicate pelareorep-induced changes in blood T cell populations may be a predictive biomarker Advanced collaboration with Roche and AIO by initiating dosing in phase 1/2 GOBLET trial in gastrointestinal cancers Strong financial position with approxim
Read more →Multi-center trial is being conducted in collaboration with Roche and AIO Trial is designed to assess the safety and efficacy of pelareorep-atezolizumab combination therapies across multiple gastrointestinal cancer indications Trial builds on prior promising data from pancreati
Read more →Trial is designed to advance pelareorep's clinical development in China, the world's second-largest pharmaceutical market SAN DIEGO and CALGARY, AB, Oct. 14, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that its partner Adlai Nortye has
Read more →SAN DIEGO and CALGARY, AB, Sept. 20, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced preclinical data demonstrating the synergistic immunotherapeutic effects of pelareorep combined with radiotherapy in a murine cancer model. The data were f
Read more →- Clinical AWARE-1 trial achieves primary endpoint and confirms that pelareorep is an immunotherapeutic agent which synergizes with checkpoint inhibitors: Validation of clinical development strategy in breast cancer - Phase 2 BRACELET-1 (breast cancer) trial remains on track for
Read more →SAN DIEGO and CALGARY, AB, Aug. 6, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference, which is taking place virtually from August 10-1
Read more →Interim Consolidated Financial Statements Oncolytics Biotech Inc. June 30, 2021 and 2020 ONCOLYTICS BIOTECH INC. INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (in Canadian dollars, except share amounts) As at Notes June 30, 2021 $ December 31, 2020 $ Assets Curre
Read more →Conference call and webcast to take place on Friday, August 6, 2021, at 8:00 a.m. ET SAN DIEGO and CALGARY, AB, July 22, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, August 6, 2
Read more →SAN DIEGO and CALGARY, AB, June 30, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will present a corporate overview at the Ladenburg Thalmann Healthcare Conference, which is taking place virtually from July 13-14, 2021. P
Read more →SAN DIEGO, Calif. and CALGARY, AB, May 20, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced clinical and biomarker data demonstrating clinical proof-of-concept for pelareorep-checkpoint inhibitor combination therapy in pancreatic cancer. The
Read more →Fireside chat to take place on Wednesday, May 19 at 5:25 pm ET SAN DIEGO and CALGARY, AB, May 13, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will participate in a virtual fireside chat at the 2021 RBC Capital Markets
Read more →- AWARE-1 clinical data validate clinical development strategy by confirming pelareorep's anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize with checkpoint inhibitors - Preclinical studies show that pelareorep's synergi
Read more →Interim Consolidated Financial Statements Oncolytics Biotech Inc. March 31, 2021 and 2020 ONCOLYTICS BIOTECH INC. INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (in Canadian dollars, except share amounts) As at Notes March 31, 2021 $ December 31, 2020 $ Assets Cur
Read more →Management will also provide its annual corporate update after the conclusion of the meeting SAN DIEGO, Calif. and CALGARY, AB, April 30, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), (the "Company") today announced that its upcoming 2021 Annual Genera
Read more →SAN DIEGO and CALGARY, AB, April 29, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of an abstract discussing its pancreatic adenocarcinoma trial at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which
Read more →- Pelareorep and atezolizumab synergize the anti-cancer immune response in HR+/HER2- breast cancer patients - Pelareorep alone and with checkpoint blockade converts tumors to PD-L1 positive classification - Oncolytics validates that pelareorep significantly improves immunothera
Read more →SAN DIEGO and CALGARY, AB, April 12, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) recently announced preclinical data highlighting pelareorep's ability to synergize with multiple classes of anti-cancer agents. The data are featured in two electronic pos
Read more →SAN DIEGO and CALGARY, Alberta, April 8, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, the Company's President and Chief Executive Officer, will be participating in a panel discussion at the Canaccord Genuity Horizon
Read more →SAN DIEGO and CALGARY, AB, April 5, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a Key Opinion Leader (KOL) webinar discussing AWARE-1 data, the immunotherapeutic effects of pelareorep in breast cancer, and its synergis
Read more →SAN DIEGO and CALGARY, AB, March 10, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will present updated clinical data from its AWARE-1 window-of-opportunity study in patients with early-stage breast cancer, as well as results from
Read more →- New clinical data highlight pelareorep's potential to boost the effectiveness of checkpoint inhibitors - Clinical demonstration of pelareorep reversing immunosuppressive tumor microenvironments - On track to report clinical biomarker and safety data in breast cancer in 2021
Read more →SAN DIEGO, Calif. and CALGARY, AB, March 5, 2021 /PRNewswire/ ---- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it has entered into an at-the-market (ATM) equity offeri
Read more →distribution AGREEMENT Canaccord Genuity LLC 99 High Street, 12th Floor Boston, Massachusetts 02110 Ladies and Gentlemen: Inc., a company incorporated under the Business Corporations Act (Alberta) (the "Company"), confirms its agreement (this "Agreement") with Canaccord Gen
Read more →SAN DIEGO, Calif. and CALGARY, AB, Feb. 26, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, March 5, 2021, at 8:30 am ET to discuss a corporate update and financial results for the
Read more →Mayo Clinic shows pelareorep vastly improved persistence and efficacy of CAR T cell therapy leading to cures in this model Pelareorep's synergistic effects with CAR T therapy appear to be specific and were not observed with the oncolytic virus VSV Results demonstrate the potent
Read more →- Pelareorep strongly increases CelTIL score, the primary endpoint and a measure of tumor cellularity and inflammation associated with favorable clinical outcomes - Pelareorep increased tumor PD-L1 expression 105-fold, thereby making the tumors more amenable to immuno-checkpoint
Read more →SAN DIEGO, Calif. and CALGARY, Alberta, Nov. 19, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced positive results from ReoGlio, an investigator-sponsored, phase 1b trial evaluating the combination of pelareorep and granulocyte-macrophage co
Read more →SAN DIEGO, Calif. and CALGARY, Alberta, Nov. 17, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of three abstracts for electronic poster presentations to be given as part of the 2020 San Antonio Breast Cancer Symposium, whi
Read more →SAN DIEGO, and CALGARY, AB, Nov. 11, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and operational highlights for the quarter ended September 30, 2020. All dollar amounts are expressed in Canadian currency unless oth
Read more →- AWARE-1 data support the results of a prior phase 2 trial that showed a near doubling of overall survival with pelareorep treatment in HR+/HER2- breast cancer patients - Data show pelareorep-induced generation and expansion of anti-tumor T cell clones that may contribute to a
Read more →SAN DIEGO, CA and CALGARY, AB, Nov. 9, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. [NASDAQ: ONCY] [TSX: ONC] today announced the publication of an abstract for an oral presentation to be given as part of the virtual 2020 Society of Neuro-Oncology (SNO) Annual Meeting. The abstr
Read more →Multi-center trial to assess the safety and efficacy of pelareorep-atezolizumab combination therapies across multiple GI cancer indications Treatment aimed at 4.8M global GI cancer cases annually1 and the approximately 80% of GI cancer patients who do not respond to immune check
Read more →SAN DIEGO and CALGARY, AB, Oct. 7, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will be participating in the BIO Investor Forum Digital, which is taking place virtually from October 13-15, 2020. The Company's profile fo
Read more →SAN DIEGO and CALGARY, Alberta, Sept. 1, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will be presenting a corporate overview at the following investor conferences in September: LD Micro 500 Virtual Investor Conference
Read more →- Expansion of Oncolytics' lead breast cancer program into a new disease subtype - Seek synergies between pelareorep and retifanlimab checkpoint inhibitor SAN DIEGO, Calif. and CALGARY, Alberta, Aug. 26, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) to
Read more →SAN DIEGO, Calif. and CALGARY, AB, Aug. 10, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will participate in a virtual fireside chat at the Canaccord Genuity 40th Annual Growth Conference. Presentation details are listed
Read more →SAN DIEGO and CALGARY, Alberta, Aug. 4, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and operational highlights for the quarter ended June 30, 2020. All dollar amounts are expressed in Canadian currency unless other
Read more →SAN DIEGO and CALGARY, Alberta, June 25, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced a new investigator-sponsored triple-negative breast cancer (TNBC) study to be managed by Rutgers Cancer Institute of New Jersey. The phase 2 trial, kn
Read more →SAN DIEGO and CALGARY, Alberta, June 23, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the first patient has been dosed in the Company's phase 2 study of pelareorep-based combination therapies in HR+/HER2- metastatic breast cancer (mBC).
Read more →Canaccord Genuity LLC 99 High Street, 12th Floor Boston, Massachusetts 02110 Ladies and Gentlemen: Inc., a company incorporated under the Business Corporations Act (Alberta) (the "Company"), confirms its agreement (this "Agreement") with Canaccord Genuity LLC ("Canaccord"),
Read more →SAN DIEGO, California and CALGARY, Alberta, June 4, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today provided a recap of a Key Opinion Leader (KOL) call sponsored by Canaccord Genuity and held on June 2, 2020. The call focused on recently announced c
Read more →SAN DIEGO and CALGARY, Alberta, May 14, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of two abstracts in connection with the upcoming AS
Read more →SAN DIEGO and CALGARY, Alberta, May 13, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Matt Coffey, President & CEO of Oncolytics Biotech, will prese
Read more →Interim Consolidated Financial Statements Oncolytics Biotech Inc. March 31, 2020 and 2019 ONCOLYTICS BIOTECH INC. INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION As at Notes March 31, 2020 $ December 31, 2019 $ Assets Current assets Cash and cash equivalents
Read more →SAN DIEGO and CALGARY, Alberta, April 30, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), (the "Company") today announced that in light of the ongoing COVID-19 pandemic, it is taking precautionary measures for its upcoming 2020 Annual General Meeting (the
Read more →SAN DIEGO, California and CALGARY, Alberta, April 17, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today provided an update on the potential impact of COVID-19 on the C
Read more →NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 7, MANAGEMENT INFORMATION CIRCULAR Important Notice regarding Participation in the Annual Meeting of Shareholders on May 7, 2020 health of our shareholders and our employees is the top priority for Oncolytics
Read more →SAN DIEGO and CALGARY, Alberta, April 2, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced positive clinical data published in a peer-reviewed journal highli
Read more →SAN DIEGO, California and CALGARY, Alberta, March 24, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced a favourable assessment from the Safety Committee fol
Read more →SAN DIEGO and CALGARY, Alberta, March 5, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its financial results and operational highlights for the quarter a
Read more →SAN DIEGO and CALGARY, Alberta, Feb. 28, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will host a conference call for Analysts and Institutional
Read more →Interim Consolidated Financial Statements Oncolytics Biotech Inc. September 30, 2019 and 2018 ONCOLYTICS BIOTECH INC. INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION As at Notes September 30, 2019 $ December 31, 2018 $ Assets Current assets Cash and cash equi
Read more →UNDERWRITING AGREEMENT 4,619,773 Common Shares ONCOLYTICS BIOTECH Inc. under the Business Corporations Act (Alberta)) Ladenburg Thalmann & Co. Inc. 277 Park Avenue, 26th Floor As Representative of the several Underwriters c/o Ladenburg Thalmann & Co. Inc. 277 Park Avenue,
Read more →Interim Consolidated Financial Statements Oncolytics Biotech Inc. June 30, 2019 and 2018 ONCOLYTICS BIOTECH INC. INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION As at Notes June 30, 2019 $ December 31, 2018 $ Assets Current assets Cash and cash equivalents 4
Read more →Oncolytics Biotech announced the first patient treated in a phase 1 study combining pelareorep, carfilzomib, and Opdivo for relapsed multiple myeloma. The study aims to determine the maximum tolerated dose and assess side effects while exploring biomarker responses. The trial is based on previous findings indicating potential effectiveness of the combination therapy.
Read more →Oncolytics Biotech presented data at the ASH Annual Meeting showing that pelareorep, when combined with a proteasome inhibitor, increases PD-L1 expression in relapsed myeloma patients. This phase 1 study involved 15 patients and suggests pelareorep could serve as a foundational treatment for immune checkpoint therapy. Further studies are planned to explore its efficacy with additional checkpoint inhibitors.
Read more →Oncolytics Biotech has appointed Dr. Rita Laeufle as Chief Medical Officer to oversee the clinical development of pelareorep, an immuno-oncolytic virus. Dr. Laeufle brings extensive experience in oncology and will lead efforts towards a phase 3 registration study in metastatic breast cancer. Her background includes significant roles in drug development and a focus on gastrointestinal cancers.
Read more →Oncolytics Biotech has initiated a Phase 2 study to evaluate the combination of pelareorep and Keytruda in patients with advanced pancreatic adenocarcinoma. The study aims to assess the overall response rate and safety of the treatment. Previous studies indicated positive responses, and the trial will enroll up to 30 patients, contingent on meeting predefined response criteria.
Read more →CALGARY, Alberta and SAN DIEGO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the Company is scheduled to attend the following upcoming
Read more →Oncolytics Biotech reported its third quarter financial results for 2018, highlighting significant clinical advancements with pelareorep, an immuno-oncolytic virus. The company is preparing to initiate a registration study in metastatic breast cancer, leveraging its findings on immune response mechanisms. Management expressed optimism about the upcoming AWARE-1 study in collaboration with Roche's Tecentriq.
Read more →Oncolytics Biotech announced that data presented at the SITC 2018 Annual Meeting demonstrates its oncolytic virus, pelareorep, can upregulate PD-L1 expression in prostate cancer cells. This finding suggests that pelareorep may enhance the effectiveness of immune checkpoint inhibitors, potentially improving treatment outcomes for patients with traditionally difficult-to-treat prostate cancers. The study highlights the importance of combining oncolytic virotherapy with immunotherapy.
Read more →Oncolytics Biotech will hold a conference call on November 12, 2018, to discuss its third quarter financial results and corporate highlights. The company is focused on developing pelareorep, an immuno-oncolytic virus, and is preparing for a phase 3 study in metastatic breast cancer. The call will be accessible via phone and webcast.
Read more →Oncolytics Biotech announced an abstract for the ASH Annual Meeting, highlighting pelareorep's potential to increase PD-L1 expression when combined with carfilzomib in myeloma patients. The study showed promising clinical responses, indicating pelareorep's role as a candidate for combination therapies with immune checkpoint inhibitors. The full details will be presented at the conference.
Read more →Canaccord Genuity LLC 99 High Street, 12th Floor Boston, Massachusetts 02110 Ladies and Gentlemen: Inc., a company incorporated under the Business Corporations Act (Alberta) (the "Company"), confirms its agreement (this "Agreement") with Canaccord Genuity LLC ("Canaccord"),
Read more →- Pelareorep more than doubles overall survival at recommended phase two dose as compared to historical phase 3 data - CALGARY, Alberta and SAN DIEGO, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intra
Read more →- Pelareorep and FOLFIRI/B combination shows superior OS & PFS data in KRAS mutant colorectal cancer compared to historical data - CALGARY, Alberta and SAN DIEGO, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareore
Read more →CALGARY, Alberta and SAN DIEGO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced publication of important research in t
Read more →CALGARY, Alberta and SAN DIEGO, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY), (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced the execution of a Common Stock Purc
Read more →THIS PURCHASE AGREEMENT (the "Agreement"), dated as of September 27, 2018 (the "Execution Date"), is entered into by and between ONCOLYTICS BIOTECH INC., a company incorporated under the Business Corporations Act (Alberta) (the "Company"), and LINCOLN PARK CAPITAL FUND, LLC, a
Read more →CALGARY, Alberta and SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX: ONC) (NASDAQ: ONCY), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that it will present at the Ladenburg
Read more →- Webcast and conference call for investors and analysts on Thursday, September 20 at 8:30 a.m. EDT - CALGARY, Alberta and SAN DIEGO, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX: ONC) (NASDAQ: ONCY), currently developing pelareorep, an intravenously deliver
Read more →CALGARY, Alberta and SAN DIEGO, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX: ONC) (NASDAQ: ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced a second study in multipl
Read more →CALGARY, Alberta and SAN DIEGO, Calif., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced a clinical collab
Read more →CALGARY, Alberta and SAN DIEGO, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that it has entered into
Read more →CALGARY, Alberta and SAN DIEGO, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced financial results and oper
Read more →CALGARY, Alberta and SAN DIEGO, July 31, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (NASDAQ:ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that it will present at the
Read more →CALGARY, Alberta and SAN DIEGO, June 05, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (NASDAQ:ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced the closing of its previousl
Read more →Oncolytics Biotech Announces Poster Presentation Demonstrating the Ability of REOLYSIN to Promote and Predict Response to Checkpoint Inhibitors at ASCO 2018 Annual Meeting CALGARY, AB and SAN DIEGO, CA, June 4, 2018 - Oncolytics Biotech Inc. (TSX: ONC) (NASDAQ: ONCY), current
Read more →Oncolytics Biotech Announces Listing on Nasdaq Capital Market CALGARY, AB and SAN DIEGO, June 1, 2018 - Oncolytics Biotech Inc. (TSX: ONC) (NASDAQ: ONCY), currently developing REOLYSIN (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, to
Read more →UNDERWRITING AGREEMENT 1,372,213 Common Shares ONCOLYTICS BIOTECH Inc. under the Business Corporations Act (Alberta)) Ladenburg Thalmann & Co. Inc. 277 Park Avenue, 26th Floor As Representative of the several Underwriters c/o Ladenburg Thalmann & Co. Inc. 277 Park Avenue,
Read more →CALGARY, Alberta and SAN DIEGO, June 01, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (NASDAQ:ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced the pricing of its underwrit
Read more →Oncolytics Biotech Announces Public Offering of Common Shares CALGARY, AB and SAN DIEGO, CA, May 31, 2018 -- Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYD), currently developing REOLYSIN (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors ho
Read more →CALGARY, Alberta and SAN DIEGO, May 29, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYD), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that following its share cons
Read more →CALGARY, Alberta and SAN DIEGO, May 25, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced a collaboration with the Keck
Read more →CALGARY, Alberta and SAN DIEGO, May 22, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that it has applied to list i
Read more →CALGARY, Alberta and SAN DIEGO, May 17, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced an investigator sponsored stu
Read more →Oncolytics Biotech Announces Publication of REOLYSIN Abstract for the ASCO 2018 Annual Meeting CALGARY, AB and SAN DIEGO, CA, May 16, 2018 -- Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF), currently developing REOLYSIN (pelareorep), an intravenously delivered immuno-onco
Read more →CALGARY, Alberta and SAN DIEGO, May 11, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced financial results and operati
Read more →CALGARY, Alberta and SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that it has reached an agreem
Read more →CALGARY, Alberta and SAN DIEGO, May 04, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced the voting results from its A
Read more →Oncolytics Biotech Announces Details of 2018 Annual General Meeting of Shareholders CALGARY, AB and SAN DIEGO, CA, April 26, 2018 - Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF), currently developing REOLYSIN (pelareorep), an intravenously delivered immuno-oncolytic virus
Read more →NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 3, MANAGEMENT INFORMATION CIRCULAR NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS 1 MANAGEMENT INFORMATION CIRCULAR 2 APPOINTMENT OF PROXY HOLDERS 2 REVOCABILITY OF PROXY 3 SIGNING OF PROXY 3 VOTING OF SHARES
Read more →Oncolytics Biotech to Host Conference Call Outlining the Treatment Paradigm of Metastatic Breast Cancer Subtypes and Provide Topline Information on its Phase 3 Registration Study with REOLYSIN - Featuring Dr. Aleix Prat, Head of Medical Oncology at Hospital Cl nic of Barcelona
Read more →Oncolytics Biotech Inc. Announces Plans to Apply to List Common Shares on the NASDAQ Capital Market - Special meeting of shareholders to be held on February 23, 2018 to vote on the proposal - CALGARY, AB and SAN DIEGO, CA, January 29, 2018 -- Oncolytics Biotech Inc. (TSX: ONC)
Read more →Oncolytics Biotech Named to the 2018 OTCQX Best 50 CALGARY, AB and SAN DIEGO, January 25, 2018 -- Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF), a biotech company developing REOLYSIN , also known as pelareorep, an intravenously delivered immuno-oncolytic virus that activates
Read more →Oncolytics Biotech Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas CALGARY, AB and SAN DIEGO, CA, January 19, 2018 --- Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: O
Read more →Oncolytics Biotech Announces Abstract for Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas CALGARY, AB and SAN DIEGO, CA, January 16, 2018 --- Oncolytics Biotech Inc. (TSX: O
Read more →Oncolytics Biotech Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas CALGARY and SAN DIEGO, CA, Dec. 27, 2017 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONC
Read more →Oncolytics Biotech Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN in Metastatic Breast Cancer CALGARY and SAN DIEGO, CA, Dec. 5, 2017 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech compan
Read more →Oncolytics Biotech to Present at the Oncolytic Virotherapy Dr. Matt Coffey, Oncolytics' President & Chief Executive Officer, to present on the clinical progress of using reovirus as an immuno-oncology viral agent to treat CALGARY and SAN DIEGO, CA, Dec. 4, 2017 /CNW/ - Oncolyt
Read more →Oncolytics Biotech Establishes Scientific Advisory Board Focused on REOLYSIN Registration Study in Metastatic Breast Cancer CALGARY and SAN DIEGO, Nov. 30, 2017 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing
Read more →Oncolytics Biotech Inc. and Adlai Nortye Enter into USD $86.6 Million Regional Licensing Agreement for REOLYSIN CALGARY and SAN DIEGO, CA, Nov. 16, 2017 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN
Read more →Oncolytics Biotech Inc. Announces 2017 Third Quarter CALGARY, and SAN DIEGO, CA, Nov. 8, 2017 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN , an intravenously delivered immuno-oncolytic virus that a
Read more →Oncolytics Biotech Appoints Deborah Brown to Board CALGARY and SAN DIEGO, CA, Nov. 2, 2017 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN , an intravenously delivered immuno-oncolytic virus that acti
Read more →Oncolytics Biotech to Present at the 2017 BIO Investor Presenting clinical data of REOLYSIN in metastatic breast cancer and the Company's strategic objectives CALGARY and SAN DIEGO, Oct. 11, 2017 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF), a biotech company de
Read more →Oncolytics Biotech to Present at the Phacilitate Immuno-Oncology Frontiers Conference Dr. Andres Gutierrez, Oncolytics' Chief Medical Officer, to present on the clinical progress and robust safety findings of using reovirus as an immuno-oncology viral agent to treat cancer C
Read more →Oncolytics Biotech Announces Successful End-of-Phase 2 Meeting with FDA for REOLYSIN in Metastatic Breast Cancer Outcome supports focus on HR+/HER2- patient group that reported an effective doubling of median overall survival from 10.8 to 21.0 months CALGARY and SAN DIEGO, S
Read more →Oncolytics Biotech Announces First Patient Treated CALGARY and SAN DIEGO, Sept. 14, 2017 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN (pelareorep), a first-in-class, systemically delivered immuno-o
Read more →Oncolytics Biotech Announces the Presentation of REOLYSIN Clinical Data at ESMO 2017 Congress Additional randomized phase 2 data in metastatic breast cancer demonstrates doubling of overall survival in Hormone Receptor Positive (ER+PR+)/HER2- patients Largest immuno-oncolytic
Read more →Oncolytics Biotech Inc. Announces 2017 Second Quarter CALGARY and SAN DIEGO, CA, Aug. 3, 2017 /CNW/ - Oncolytics Biotech Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) today announced its financial results and operational highlights for the quarter ended June 30, 201
Read more →Oncolytics Biotech Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference CALGARY, AB and SAN DIEGO, CA, Aug. 1, 2017 /CNW/ - Oncolytics Biotech Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) will present at the Canaccord Genuity 37th Annual Growth C
Read more →Oncolytics Biotech to Present REOLYSIN Safety Data in combination with chemotherapy at ESMO 2017 Congress Announces end-of-phase 2 meeting with the U.S. Food and Drug Administration CALGARY and SAN DIEGO, July 26, 2017 /CNW/ - Oncolytics Biotech Inc. (Oncolytics or the Compa
Read more →Oncolytics Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (U.S.) Inc. Responsible for Global Partnering and Business Development CALGARY and SAN DIEGO, June 29, 2017 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Com
Read more →Oncolytics Biotech Inc. Opens U.S. Based Office CALGARY and SAN DIEGO, June 27, 2017 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company) today announced that it has opened an office in San Diego, California. The office will support investor re
Read more →Oncolytics Biotech Announces Closing of Public Offering CALGARY, June 1, 2017 /CNW/ - Oncolytics Biotech Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) today announced the closing of its previously announced underwritten public offering. Oncolytics sold 16,445,000 un
Read more →Oncolytics Biotech Prices Public Offering of Units CALGARY, May 24, 2017 /CNW/ - Oncolytics Biotech Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) today announced the pricing of an underwritten public offering of 14,300,000 units (Units) at a purchase price of $0.70
Read more →Oncolytics Biotech Announces Proposed Public Offering CALGARY, May 23, 2017 /CNW/ - Oncolytics Biotech Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) today announced that it will undertake a public offering (the "Offering") of securities of the Company ("Securities")
Read more →Oncolytics Biotech Inc. Announces Participation in World Immunotherapy Congress USA 2017 CALGARY, May 23, 2017 /CNW/ - Oncolytics Biotech Inc. (TSX:ONC) (OTCQX:ONCYF) (Oncolytics or the Company) today announced that Dr. Andres A. Gutierrez, Chief Medical Officer of Oncolytics
Read more →Oncolytics Biotech Announces ASCO Abstracts and Preliminary Data for Studies in Pancreatic and Prostate Cancers CALGARY, May 17, 2017 /CNW/ - Oncolytics Biotech Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) today announced the publication of abstracts for an open-la
Read more →Oncolytics Biotech Inc. Announces FDA Fast Track Designation for REOLYSIN in Metastatic Breast Cancer CALGARY, May 8, 2017 /CNW/ - Oncolytics Biotech Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) announced today that the United States Food and Drug Administration (F
Read more →Oncolytics Biotech Inc. Announces 2017 First Quarter CALGARY, May 5, 2017 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company) today announced its financial results and operational highlights for the quarter ended March 31, 2017. "The last six
Read more →Oncolytics Biotech Inc. Announces Voting Results from its Annual Meeting of Shareholders CALGARY, May 4, 2017 /CNW/ - Oncolytics Biotech Inc. (Oncolytics or the Corporation) (TSX:ONC) (OTCQX:ONCYF) today announced the voting results from its Annual Meeting of Shareholders hel
Read more →Oncolytics Biotech Inc. Announces Details of 2017 Annual Meeting of Shareholders CALGARY, April 27, 2017 /CNW/ - Oncolytics Biotech Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) announced today that its 2017 Annual Meeting of Shareholders will be held on Thursday,
Read more →Oncolytics Biotech Inc. to Present at the Sixth Annual Bloom Burton & Co. Healthcare Investor Conference CALGARY, April 26, 2017 /CNW/ - Oncolytics Biotech Inc. (TSX:ONC) (OTCQX:ONCYF) (Oncolytics or the Company), will participate in the Bloom Burton & Co. Healthcare Investor
Read more →NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 4, 2017 MANAGEMENT INFORMATION CIRCULAR NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS 1 MANAGEMENT INFORMATION CIRCULAR 2 APPOINTMENT OF PROXY HOLDERS 2 REVOCABILITY OF PROXY 2 SIGNING OF PROXY 3 VOTING OF S
Read more →Oncolytics Biotech Inc. Announces Registration Pathway and Clinical Development Plan --Initial Registration Pathway to Focus on Chemotherapy Combinations in Patients with Metastatic Breast Cancer-- CALGARY, April 12, 2017 /CNW/ - Oncolytics Biotech Inc. (TSX:ONC) (OTCQX:ONC
Read more →Oncolytics Biotech Inc.'s REOLYSIN More than Doubles Overall Survival in Patients with Mutated p53 Metastatic Breast Cancer CALGARY, April 5, 2017 /CNW/ - Oncolytics Biotech Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) today announced data demonstrating a statistic
Read more →Oncolytics Biotech Inc.'s REOLYSIN Provides Statistically Significant Improvement in Overall Survival in Canadian Cancer Trials Group Sponsored Randomized Phase 2 Study in Metastatic Breast Cancer CALGARY, March 31, 2017 /CNW/ - Oncolytics Biotech Inc. (Oncolytics or the Comp
Read more →Oncolytics Biotech Inc. Enters into First-in-Class Collaboration with Myeloma UK and Celgene Using REOLYSIN in Combination with Imnovid or Revlimid in Patients with CALGARY, March 16, 2017 /CNW/ - Oncolytics Biotech Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) toda
Read more →Oncolytics Biotech Inc. Announces 2016 Year-End CALGARY, March 10, 2017 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company) today announced its financial results and operational highlights for the year ended December 31, 2016. "It was a year
Read more →Oncolytics Biotech Inc. Announces Canadian Cancer Trials Group to Present Final Randomized Data from Phase 2 Metastatic Breast Cancer Study at AACR 2017 Annual Meeting CALGARY, March 2, 2017 /CNW/ - Oncolytics Biotech Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) to
Read more →Oncolytics Biotech Inc. Appoints Dr. Matt Coffey to the Role of President and CEO CALGARY, Jan. 19, 2017 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX: ONC) (OTCQX: ONCYF) today announced that Matt Coffey PhD, MBA, has been appointed to the role of Pres
Read more →Oncolytics Biotech Inc. Announces Change to Board of Directors CALGARY, Dec. 6, 2016 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX: ONC) (OTCQX: ONCYF) today announced that Dr. Brad Thompson has resigned from Oncolytics board of directors effective immed
Read more →Oncolytics Biotech Inc. Collaborators Present Initial Results from REO 019 Study in Multiple Myeloma Combining REOLYSIN , Bortezomib and Dexamethasone at the ASH Annual Meeting -- Preliminary data suggest evidence of activity and that the treatment combination was well tolerat
Read more →Oncolytics Biotech Inc. Announces Appointment of New Chief -- Andres A. Gutierrez MD, PhD to Lead Development of Late Stage Clinical Program & Registration Strategy -- CALGARY, Nov. 10, 2016 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX: ONC) (OTCQX: ON
Read more →Oncolytics Biotech Inc. Announces 2016 Third Quarter Results CALGARY, Nov. 3, 2016 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the third quarter ended
Read more →Interim Consolidated Financial Statements Oncolytics Biotech Inc. September 30, 2016 and 2015 ONCOLYTICS BIOTECH INC. INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION Notes September 30, 2016 $ December 31, 2015 $ Assets Current assets Cash and cash equivalen
Read more →Media Advisory - Oncolytics Biotech Inc. Announces Management CALGARY, Nov. 2, 2016 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) today announced that Brad Thompson Ph.D. has stepped down as President and Chief Executive O
Read more →Media Advisory - Oncolytics Biotech Inc. Announces Participation in the 2016 BIO Investor Forum CALGARY, Oct. 18, 2016 /CNW/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY), will present at the 2016 BIO Investor Forum in a
Read more →Media Advisory - Oncolytics Biotech Inc. Announces Participation in the 4th Annual Immuno-Oncology Summit CALGARY, Aug. 30, 2016 /CNW/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY), will present at the 4th Annual Immuno-
Read more →MEDIA ADVISORY - Oncolytics Biotech Inc. Announces Participation in the Canaccord Genuity 36th Annual Growth Conference CALGARY, Aug. 10, 2016 /CNW/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY), will present at the 36th
Read more →Oncolytics Biotech Inc. Reports Additional Data from Randomized Phase II Study of REOLYSIN in Non-Small Cell Lung Cancer --Study Demonstrates Statistically Significant Improvement in Progression Free Survival in Female Patients with Adenocarcinoma-- CALGARY, Aug. 10, 2016 /CN
Read more →Oncolytics Biotech Inc. Announces 2016 Second Quarter Results CALGARY, Aug. 4, 2016 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the second quarter ende
Read more →Oncolytics Biotech Inc. Announces Phase 2 Study in Female Patients with Colorectal Cancer Metastatic to the Liver CALGARY, June 29, 2016 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) today announced that, following submiss
Read more →Oncolytics Biotech Inc. Reports Preliminary Data from Randomized Phase II Study of REOLYSIN in Colorectal Cancer --REOLYSIN Demonstrates Increase in Objective Response Rates in Female Patients and in Patients with Liver Metastases-- CALGARY, May 19, 2016 /CNW/ - Oncolytics B
Read more →Interim Consolidated Financial Statements Oncolytics Biotech Inc. March 31, 2016 and 2015 ONCOLYTICS BIOTECH INC. INTERM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION As at Notes March 31, 2016 $ December 31, 2015 $ Assets Current assets Cash and cash equivalents 3
Read more →Oncolytics Biotech Inc. Announces 2016 First Quarter Results CALGARY, May 6, 2016 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the first quarter ended M
Read more →Oncolytics Biotech Inc. Announces Presentation of REOLYSIN Preclinical Research at the 2016 ASGCT Annual Meeting CALGARY, May 5, 2016 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) today announced a poster presentation by
Read more →Oncolytics Biotech Inc. Announces Details of 2016 Annual Meeting of Shareholders CALGARY, May 3, 2016 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) announced today that its 2016 Annual Meeting of Shareholders will be held
Read more →Oncolytics Biotech Inc. to Participate in the Bloom Burton & Co. Healthcare Investor Conference CALGARY, April 29, 2016 /CNW/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) ("Oncolytics" or the "Company"), will participa
Read more →Oncolytics Biotech Inc. Announces Formation of Science and Technology Committee CALGARY, April 29, 2016 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) ("Oncolytics" or the "Company") today announced the formation of a Science and Technology Committee mad
Read more →Oncolytics Biotech Inc. Collaborators Present REOLYSIN Preclinical Research at the 2016 AACR Annual Meeting CALGARY, April 18, 2016 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) today announced that two poster presentatio
Read more →Oncolytics Biotech Inc. Reports Updated Data from Randomized Phase 2 Study of REOLYSIN in Pancreatic Cancer --Intent-to-Treat Analysis Shows Statistically Significant Increase in 2-Year Survival-- CALGARY, April 14, 2016 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONC
Read more →Oncolytics Biotech Inc. Announces Filing of Management Information Circular and Details of 2016 Annual General Meeting CALGARY, March 24, 2016 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) announced today that the Company
Read more →Oncolytics Biotech Inc. Reports Data from Randomized Phase 2 Study of REOLYSIN in Ovarian Cancer --Intent-to-Treat Analysis Shows Statistically Significant Reduction in Tumour Burden as Measured by CA-125-- CALGARY, March 21, 2016 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC) (
Read more →Oncolytics Biotech(R) Inc. Announces 2015 Year End Results CALGARY, March 11, 2016 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the year ended December
Read more →/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ Oncolytics Biotech Inc. Announces $4.6 Million "At-The-Market" Equity Financing Program CALGARY, AB, February 25, 2016 --- Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX: ON
Read more →Media Advisory - Oncolytics Biotech Inc. Announces Participation in Upcoming Conferences CALGARY, Feb. 8, 2016 /CNW/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY), will present at the 18th Annual BIO CEO & Investor Conf
Read more →Oncolytics Biotech Inc. Announces First Patients Treated in Phase 1b Study in Advanced Pancreatic Cancer CALGARY, Jan. 19, 2016 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that the first patients have been treated in a Phase 1b study
Read more →Oncolytics Biotech Inc. Collaborators Present Multiple Myeloma Data at 57th American Society of Hematology Annual Meeting -- Emerging Data Support Conducting Additional, Later Stage Studies in Multiple Myeloma -- CALGARY, Dec. 8, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncoly
Read more →MEDIA ADVISORY - Oncolytics Biotech Inc. to Present at LD Micro Growth Conference CALGARY, Dec. 2, 2015 /CNW/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, OTCQX: ONCYF), will participate in and present at the LD Micro Conference today, Wednesda
Read more →Oncolytics Biotech Inc. Announces Start of Enrollment in Phase 1b Study of Multiple Myeloma Looking at REOLYSIN in Combination with Bortezomib CALGARY, Nov. 18, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, OTCQX:ONCYF) today announced that enrollment has comme
Read more →Interim Consolidated Financial Statements Oncolytics Biotech Inc. September 30, 2015 and 2014 ONCOLYTICS BIOTECH INC. INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION Notes September 30, 2015 $ December 31, 2014 $ Assets Current assets Cash and cash equivalen
Read more →Biotech Inc. Announces 2015 Third Quarter Results Nov. 5, 2015 /CNW/ - Oncolytics Biotech Inc. (TSX:ONC, OTCQX:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the third quarter ended September 30, 2015. the quarter, we
Read more →Oncolytics Biotech Inc. Announces Receipt of Qualification for Trading on the OTCQX and Nasdaq Notice of Delisting CALGARY, Oct. 29, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ:ONCY) announced today that it has received notification f
Read more →Oncolytics Biotech Inc. Announces Phase 1b Study in Advanced Pancreatic Cancer -- First Clinical Trial Examining Effects of REOLYSIN in Combination with a Checkpoint Inhibitor -- CALGARY, Oct. 20, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) to
Read more →Media Advisory - Oncolytics Biotech Inc. to Participate in the 14th Annual BIO Investor Forum CALGARY, Oct. 20, 2015 /CNW/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in the 14th Annual BIO Investor Forum in a s
Read more →Oncolytics Biotech Inc. Announces Completion of Enrollment in Randomized Phase II Prostate Cancer Study CALGARY, Oct. 6, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that enrollment has been completed in a randomized Phase II study
Read more →Oncolytics Biotech Inc. Collaborators Present Data from Clinical Study in Multiple Myeloma -- All Evaluable Patients to Date See Evidence of an Objective Response; Treatment Combination Associated with Statistically Significant Upregulation of CALGARY, Sept. 25, 2015 /CNW/ -
Read more →Media Advisory - Oncolytics Biotech Inc. to Participate in the Baird 2015 Healthcare Conference CALGARY, Sept. 9, 2015 /CNW/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in the Baird 2015 Healthcare Conference in
Read more →Oncolytics Biotech Inc. Collaborators to Present Survival Data from REO 016 Study in Non-Small Cell Lung Cancer --Report Near Tripling of Two-Year Survival Compared to Historical Controls-- CALGARY, Aug. 27, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASD
Read more →Oncolytics Biotech Inc. Announces Completion of Enrollment in Randomized Phase II Non-Small Cell Lung Cancer Study CALGARY, Aug. 26, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that enrollment has been completed in a randomized Ph
Read more →MEDIA ADVISORY - Oncolytics Biotech Inc. to Participate in the 35th Annual Canaccord Genuity Growth Conference CALGARY, Aug. 12, 2015 /CNW/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in the 35th Annual Canaccord
Read more →Oncolytics Biotech Inc. Announces 2015 Second Quarter Results CALGARY, Aug. 6, 2015 /CNW/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the second quarter ended June 30, 201
Read more →Interim Consolidated Financial Statements Oncolytics Biotech Inc. June 30, 2015 and 2014 ONCOLYTICS BIOTECH INC. INTERM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION Notes June 30, 2015 $ December 31, 2014 $ Assets Current assets Cash and cash equivalents 3 30,018
Read more →Oncolytics Biotech Inc. Collaborators Present Final Data from REO 017 Clinical Study in Pancreatic Cancer --Report More Than Doubling in One-Year Survival and Nearly Five-Fold Increase in Two-Year Survival as Compared to Historical Controls-- CALGARY, July 6, 2015 /CNW/ - Onc
Read more →Oncolytics Biotech Inc. Collaborators Present REOLYSIN Preclinical Data at the 9th International Conference on Oncolytic Virus Therapeutics CALGARY, June 15, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that a series of oral and p
Read more →Oncolytics Biotech Inc. Announces Director Election Results from its Annual Meeting of Shareholders CALGARY, June 9, 2015 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that all nominees listed in the management information circular dated May 6, 2015
Read more →Oncolytics Biotech Inc. Provides Update at AGM on Planned Registration Program for REOLYSIN CALGARY, June 8, 2015 /CNW/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today provided an update on its planned registration program for REOLYSIN ,
Read more →Oncolytics Biotech Inc. Announces Details of 2015 Annual Meeting of Shareholders CALGARY, June 5, 2015 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that its 2015 Annual Meeting of Shareholders will be held on Monday June 8th, 2015 at 2:30 pm CT (3:3
Read more →Media Advisory - Oncolytics Biotech Inc. to Participate in the LD Micro Invitational Conference CALGARY, June 2, 2015 /CNW/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in the LD Micro Invitational Conference in a
Read more →Oncolytics Biotech Inc. Announces Phase 1 Study in Pediatric Patients with Brain Tumors CALGARY, May 19, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that following submission to the U.S. Food and Drug Administration ("FDA") for r
Read more →NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 8, 2015 INFORMATION CIRCULAR Page Notice of Meeting i Solicitation of Proxies 1 Voting Shares and Principal Holders of Common Shares 2 Compensation Discussion and Analysis 3 Summary Compensation Table 7 Incentive Pla
Read more →Oncolytics Biotech Inc. Announces 2015 First Quarter Results CALGARY, May 7, 2015 /CNW/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the quarter ended March 31, 2015. "In
Read more →Interim Consolidated Financial Statements Oncolytics Biotech Inc. March 31, 2015 and 2014 ONCOLYTICS BIOTECH INC. INTERM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION As at Notes March 31, 2015 December 31, 2014 Assets Current assets Cash and cash equivalents 3 28,
Read more →Oncolytics Biotech Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Gastric Cancer CALGARY, May 6, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology company focused on the development of oncolytic
Read more →Oncolytics Biotech Inc. Announces Receipt of Orphan Drug Status from the EMA for Pancreatic Cancer CALGARY, April 29, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology company focused on the development of oncolytic vir
Read more →Oncolytics Biotech Inc. Announces Extension to Regain Compliance with Nasdaq's Minimum Bid Price Rule CALGARY, April 28, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ:ONCY) announced today that it has received a letter from the NASDAQ O
Read more →Oncolytics Biotech Inc. Collaborators Present REOLYSIN Preclinical Data at the 2015 AACR Annual Meeting CALGARY, April 20, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that a series of poster presentations by the Company's researc
Read more →Oncolytics Biotech Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Malignant Gliomas CALGARY, April 17, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology company focused on the development of onco
Read more →Oncolytics Biotech Inc. Presents at UK Immuno-oncology Meeting CALGARY, April 15, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that Dr. Matt Coffey, Chief Operating Officer, made a presentation titled "REOLYSIN and Immune Therapy:
Read more →Media Advisory - Oncolytics Biotech Inc. to Participate in the 14th Annual Needham Healthcare Conference CALGARY, April 13, 2015 /CNW/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in the 14th Annual Needham and Co
Read more →Oncolytics Biotech Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for Gastric Cancer CALGARY, April 7, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has submitted an application for Orphan Drug Designati
Read more →Oncolytics Biotech Inc. Presents at the 2015 Immune Checkpoint CALGARY, March 26, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that Dr. Giovanni Selvaggi MD, Vice President, Clinical Development, made a presentation titled "REOLYS
Read more →Oncolytics Biotech Inc. Announces Receipt of Orphan Drug Status from the EMA for Ovarian Cancer CALGARY, March 25, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruse
Read more →Oncolytics Biotech Inc. Announces 2014 Year End Results CALGARY, March 16, 2015 /CNW/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the year ended December 31, 2014. "The a
Read more →Oncolytics Biotech Inc. Collaborators Present Preclinical Data on the Combination of REOLYSIN and Radiotherapy in Melanoma at the Irish Association for Cancer Research Conference CALGARY, March 5, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) toda
Read more →Oncolytics Biotech Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Primary Peritoneal Cancer CALGARY, March 3, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology company focused on the development
Read more →Oncolytics Biotech Inc. Announces Completion of Enrollment in Randomized Phase II Colorectal Cancer Study CALGARY, Feb. 18, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that enrollment has been completed in a randomized Phase II s
Read more →Oncolytics Biotech Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Pancreatic Cancer CALGARY, Feb. 17, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology company focused on the development of oncol
Read more →Oncolytics Biotech Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Ovarian Cancer CALGARY, Feb. 11, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology company focused on the development of oncolyti
Read more →Oncolytics Biotech Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for High Grade Gliomas in Pediatric Patients CALGARY, Feb. 9, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has submitted an application
Read more →Oncolytics Biotech Inc. Announces Filing for Orphan Designation with the EMA for Pancreatic and Ovarian Cancers CALGARY, Dec. 22, 2014 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has submitted applications for Orphan Designatio
Read more →Oncolytics Biotech Inc. Collaborators Present REOLYSIN and Checkpoint Inhibitor Combination Preclinical Data at AACR Tumor Immunology and Immunotherapy Conference CALGARY, Dec. 4, 2014 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced a pos
Read more →Oncolytics Biotech Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for Pancreatic and Ovarian Cancers CALGARY, Dec. 2, 2014 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has submitted applications for Orphan D
Read more →Media Advisory - Oncolytics Biotech Inc. to Participate in the Stifel 2014 Healthcare Conference CALGARY, Nov. 18, 2014 /CNW/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in the Stifel 2014 Healthcare Conference i
Read more →Interim Consolidated Financial Statements Oncolytics Biotech Inc. September 30, 2014 and 2013 ONCOLYTICS BIOTECH INC. INTERM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION Notes September 30, 2014 $ December 31, 2013 $ Assets Current assets Cash and cash equivalent
Read more →Oncolytics Biotech Inc. Announces Third Quarter 2014 Results CALGARY, Nov. 6, 2014 /CNW/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the third quarter ended September 30,
Read more →Oncolytics Biotech Inc. Announces Receipt of Nasdaq Notice CALGARY, Nov. 4, 2014 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ:ONCY) announced today that on October 29, 2014 it received a letter from the NASDAQ OMX Group ("Nasdaq") stating th
Read more →ONCOLYTICS BIOTECH INC. EQUITY DISTRIBUTION AGREEMENT Canaccord Genuity Inc. 99 High Street, 12th Floor Boston, Massachusetts 02110 Ladies and Gentlemen: Oncolytics Biotech Inc., a company incorporated under the Business Corporations Act (Alberta) (the "Company"), confirms
Read more →Oncolytics Biotech Inc. Announces Entry Into $20 Million "At-The-Market" Equity Distribution Agreement with Canaccord Genuity Inc. CALGARY, Oct. 24, 2014 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ:ONCY) announced today that it has entered
Read more →Oncolytics Biotech Inc. Announces Amendment to Common Share Purchase Agreement with Lincoln Park Capital Fund, LLC CALGARY, Oct. 20, 2014 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ:ONCY) announced today that it has reached an agreement on
Read more →AMENDMENT NO. 2 TO PURCHASE AGREEMENT 2 (the "Amendment") is entered into this 20th day of October 2014 ("Amendment Effective Date"), by and between ONCOLYTICS BIOTECH INC., a company incorporated under the Business Corporations Act (Alberta), (the "Company"), and LINCOLN PARK
Read more →Oncolytics Biotech Inc. Announces Overall and KRAS-Mutated Patient Data from U.S. Randomized Phase 2 Pancreatic Cancer Study TORONTO, Sept. 16, 2014 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced overall and KRAS-mutated patient data from
Read more →210, 1167 Kensington Cr. N.W. /C O R R E C T I O N from Source -- Oncolytics Biotech Inc./ In the news release, Oncolytics Biotech Inc. Announces Completion of Patient Enrollment in U.S. Randomized Phase 2 Ovarian Cancer Study, issued 03-Sep-2014 by Oncolytics Biotech Inc. over
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Announces Participation in Upcoming Conferences CALGARY, AB, August 11, 2014 --- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present at the Wedbush 2014 Life Sciences Confer
Read more →AMENDMENT NO. 1 TO PURCHASE AGREEMENT This Amendment No. 1 (the "Amendment") is entered into this 8th day of August 2014 ("Amendment Effective Date"), by and between ONCOLYTICS BIOTECH INC., a company incorporated under the Business Corporations Act (Alberta), (the "Company"), a
Read more →Interim Consolidated Financial Statements Oncolytics Biotech Inc. June 30, 2014 and 2013 ONCOLYTICS BIOTECH INC. INTERM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION Notes June 30, 2014 $ December 31, 2013 $ Assets Current assets Cash and cash equivalents 3 16,880
Read more →210, 1167 Kensington Cr. N.W. Calgary, Alberta Canada T2N 1X7 Oncolytics Biotech Inc. Announces Second Quarter 2014 Results CALGARY, AB, August 7, 2014 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and
Read more →NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 18, 2014 INFORMATION CIRCULAR Page Notice of Meeting i Solicitation of Proxies 1 Voting Shares and Principal Holders of Common Shares 2 Compensation Discussion and Analysis 3 Summary Compensation Table 6 Incentive Pl
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Announces Completion of Patient Enrollment in U.S. Randomized Phase II Pancreatic Cancer Study CALGARY, AB, --- July 8, 2014 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced completion of patie
Read more →210, 1167 Kensington Cr. N.W. Calgary, Alberta Canada T2N 1X7 Oncolytics Biotech Inc. Announces Director Election Results from its Annual Meeting of Shareholders CALGARY, AB, June 19, 2014 --- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that all nominees l
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Announces Details of 2014 Annual Meeting of Shareholders CALGARY, AB, --- June 16, 2014 --- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that its 2014 Annual Meeting of Shareholders will be held on Wednesd
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. to Participate in Jefferies 2014 Global Healthcare Conference CALGARY, AB, June 2, 2014 --- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in the Jefferies 2014 Glo
Read more →210, 1167 Kensington Cr. N.W. Calgary, Alberta Canada T2N 1X7 Oncolytics Biotech Inc. Announces Nomination of Two New Directors CALGARY, AB, May 21, 2014 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced the nomination of Ms. Li
Read more →Interim Consolidated Financial Statements Oncolytics Biotech Inc. March 31, 2014 and 2013 ONCOLYTICS BIOTECH INC. INTERM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION As at Notes March 31, 2014 December 31, 2013 Assets Current assets Cash and cash equivalents 3 20,
Read more →210, 1167 Kensington Cr. N.W. Calgary, Alberta Canada T2N 1X7 Oncolytics Biotech Inc. Announces First Quarter 2014 Results CALGARY, AB, May 8, 2014 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and oper
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Collaborators Present Preclinical Research on Liver Cancer at UK Oncolytic Virus Conference CALGARY, AB, April 14, 2014 --- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that Dr. Adel Jebar o
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Collaborators Present Translational Brain Cancer Clinical Data and Immunomodulatory Preclinical Research at UK Oncolytic Virus Conference CALGARY, AB, April 11, 2014 --- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASD
Read more →210, 1167 Kensington Cr. N.W. Calgary, Alberta Canada T2N 1X7 Oncolytics Biotech Inc. Announces Additional Data from REO 018 Randomized Study of REOLYSIN in Head and Neck Cancers CALGARY, AB, April 8, 2014 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. to Participate in 13th Annual Needham Healthcare Conference CALGARY, AB, April 7, 2014 --- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in the 13th Annual Needham
Read more →210, 1167 Kensington Cr. N.W. Calgary, Alberta Canada T2N 1X7 Oncolytics Biotech Inc. Announces 2013 Year End Results CALGARY, AB, March 13, 2014 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operat
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. to Participate in the 34th Annual Cowen and Company Healthcare Conference CALGARY, AB, March 4, 2014 --- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in the 34th
Read more →PURCHASE AGREEMENT (the Agreement ), dated as of February 27, 2014, by and between ONCOLYTICS BIOTECH INC., a company incorporated under the Business Corporations Act (Alberta) (the Company ), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the Investo
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. to Participate in 2014 RBC Capital Markets Global Healthcare Conference CALGARY, AB, February 25, 2014 --- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in the 201
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. to Present at the 25th Annual Piper Jaffray Healthcare Conference CALGARY, AB, December 3, 2013 --- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Announces Positive Top-Line Data from REO 018 Randomized Study of REOLYSIN in Head and Neck Cancers --Company Intends to Proceed Into Follow-On Registration Study in This Indication-- CALGARY, AB, November 21, 2013 --- Onco
Read more →Interim Consolidated Financial Statements Oncolytics Biotech Inc. September 30, 2013 and 2012 ONCOLYTICS BIOTECH INC. INTERM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION Notes September 30, 2013 $ December 31, 2012 $ Assets Current assets Cash and cash equivalent
Read more →210, 1167 Kensington Cr. N.W. Calgary, Alberta Canada T2N 1X7 Oncolytics Biotech Inc. Announces Third Quarter 2013 Results CALGARY, AB, November 7, 2013 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Collaborators Present Positive Data Correlating Specific Biomarkers with Survival in NSCLC Patients Treated with REOLYSIN , Carboplatin and Paclitaxel CALGARY, AB, October 28, 2013 --- Oncolytics Biotech Inc. ("Oncolytics")
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Announces Progression Free Survival Data for Phase 2 Study of REOLYSIN in Squamous Cell Lung Cancer CALGARY, AB, October 22, 2013 --- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that a post
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Collaborators to Present Positive Clinical Trial Data at the 15th Annual World Conference on Lung Cancer CALGARY, AB, October 1, 2013 --- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that ab
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. to Present at the 2013 Wedbush PacGrow Life Sciences Management Access Conference CALGARY, AB, August 13, 2013 --- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corp
Read more →Interim Consolidated Financial Statements Oncolytics Biotech Inc. June 30, 2013 and 2012 ONCOLYTICS BIOTECH INC. INTERM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION Notes June 30, 2013 $ December 31, 2012 $ Assets Current assets Cash and cash equivalents 3 36,153
Read more →210, 1167 Kensington Cr. N.W. Calgary, Alberta Canada T2N 1X7 Oncolytics Biotech Inc. Announces Second Quarter 2013 Results CALGARY, AB, August 1, 2013 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Meets Primary Endpoint for First Stage of U.S. Phase 2 Metastatic Melanoma Trial CALGARY, AB, --- May 22, 2013 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced preliminary results from its U.S.
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. to Present at Bank of America Merrill Lynch Health Care Conference CALGARY, AB, May 14, 2013 --- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of
Read more →210, 1167 Kensington Cr. N.W. Calgary, Alberta Canada T2N 1X7 Oncolytics Biotech Inc. Announces Director Election Results from its Annual and Special Meeting of Shareholders CALGARY, AB, May 10, 2013 --- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that all
Read more →Interim Consolidated Financial Statements Oncolytics Biotech Inc. March 31, 2013 and 2012 ONCOLYTICS BIOTECH INC. INTERM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION Notes March 31, 2013 December 31, 2012 Assets Current assets Cash and cash equivalents 3 41,519,6
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Announces Details of 2013 Annual and Special Meeting of Shareholders CALGARY, AB, --- May 6, 2013 --- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that its 2013 Annual and Special Meeting of Shareholders
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. to Present at 12th Annual Needham Healthcare Conference CALGARY, AB, April 29, 2013 --- Dr. Alan J. Tuchman, Senior Vice President, Medical & Clinical Affairs and Chief Medical Officer of Oncolytics Biotech Inc. (TSX: ONC, N
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Meets Primary Overall Statistical Endpoint in U.S. Phase 2 Study of REOLYSIN in Squamous Cell Lung Cancer CALGARY, AB, March 28, 2013 --- Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC) (NASDAQ:ONCY) today
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Announces 2012 Year End Results CALGARY, AB, March 14, 2013 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the year end
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Completes Patient Enrollment in U.S. Phase 2 Study of REOLYSIN in Non-Small Cell Lung Cancer CALGARY, AB, --- March 5, 2013 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has complete
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. to Present at RBC Capital Markets 2013 Healthcare Conference CALGARY, AB, February 25, 2013 --- Dr. Matt Coffey, Chief Operating Officer of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present at the 2013 RBC Capit
Read more →Oncolytics Biotech Inc. Announces Closing of Common Share CALGARY, AB February 25, 2013 Oncolytics Biotech Inc. ( Oncolytics ) (TSX:ONC; NASDAQ:ONCY) announced today that it has closed its previously announced underwritten public offering of 8.0 million common shares, at a publ
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Announces Addition to Senior Management Team CALGARY, AB, February 20, 2013 --- Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC, NASDAQ:ONCY) today announced the appointment of Dr. Jeremy Grushcow to the rol
Read more →CONSENT OF NORTON ROSE CANADA LLP We hereby consent to the use of our name in the prospectus supplement filed by Oncolytics Biotech Inc. on February 20, 2013 under the headings Certain Canadian Federal Income Tax Considerations and Legal Matters and to the reference to our opin
Read more →Oncolytics Biotech Inc. Announces Pricing of Common Share Offering CALGARY, AB February 20, 2013 Oncolytics Biotech Inc. ( Oncolytics ) (TSX:ONC; NASDAQ:ONCY) announced today the pricing of an underwritten public offering of 8.0 million common shares, at a public offering price
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Announces Additional Positive REOLSYIN Clinical Trial Data from Phase 2 Study in Squamous Cell Carcinoma of the Lung CALGARY, AB, --- February 8, 2013 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today ann
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Announces Positive REOLSYIN Clinical Trial Data Presented at ASCO Gastrointestinal Cancers Symposium CALGARY, AB, --- January 28, 2013 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced a poster
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Announces Positive Top Line REOLYSIN Data for First Endpoint in Randomized Phase III Study in Head and Neck Cancers CALGARY, AB, December 13, 2012 --- Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC, NASDAQ
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Announces Addition to Senior Management Team CALGARY, AB, November 12, 2012 --- Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC, NASDAQ:ONCY) today announced the appointment of Mr. Kirk Look to the role of C
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Collaborators Present Positive REOLYSIN Trial Results and Research at EORTC-NCI-AACR Symposium CALGARY, AB, November 9, 2012 --- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced three poster pres
Read more →Interim Consolidated Financial Statements Oncolytics Biotech Inc. September 30, 2012 and 2011 ONCOLYTICS BIOTECH INC. INTERM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION September 30, December 31, Notes 2012 $ 2011 $ Assets Current assets Cash and cash equivale
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Completes Patient Enrollment in U.S. Phase II Clinical Trial Investigating REOLYSIN in Combination with Gemcitabine in Patients with Advanced or Metastatic Pancreatic Cancer CALGARY, AB, October 24, 2012 --- Oncolytics Biote
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Announces the Appointment of Dr. Alan J. Tuchman as Chief Medical Officer CALGARY, AB, September 28, 2012 --- Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC, NASDAQ:ONCY) today announced the appointment of
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Meets Primary Endpoint for First Stage of U.S. Phase 2 Squamous Cell Lung Cancer Clinical Trial CALGARY, AB, September 13, 2012 --- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced preliminary re
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Completes Patient Enrollment in U.K. Phase I Clinical Trial Investigating REOLYSIN in Combination with Cyclophosphamide in Patients with Advanced Malignances CALGARY, AB, --- August 16, 2012 - Oncolytics Biotech Inc. ("Oncol
Read more →Interim Consolidated Financial Statements Oncolytics Biotech Inc. June 30, 2012 and 2011 ONCOLYTICS BIOTECH INC. INTERM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION June 30, December 31, Notes 2012 $ 2011 $ Assets Current assets Cash and cash equivalents 3 33,8
Read more →210, 1167 Kensington Cr. N.W. Calgary, Alberta Canada T2N 1X7 Oncolytics Biotech Inc. Announces Second Quarter 2012 Results CALGARY, AB, August 2, 2012 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Enters into Sponsorship Agreement with NCIC CTG for Randomized Phase II Study in Advanced and Metastatic Breast Cancers CALGARY, June 21, 2012 --- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announce
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. to Present at Bloom Burton & Co. Healthcare Investor Conference CALGARY, AB, June 18, 2012 --- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ:ONCY), will present a corporate overview of the
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Announces Details of 2012 Annual and Special Meeting of Shareholders CALGARY, AB, --- June 15, 2012 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) announced today that its 2012 Annual and Special Meeting of Shareholders
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Announces Publication of Translational Clinical Trial Results in Science Translational Medicine CALGARY, AB, --- June 13, 2012 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that a paper enti
Read more →NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TO THE SHAREHOLDERS OF ONCOLYTICS BIOTECH INC.: NOTICE IS HEREBY GIVEN that the annual and special meeting (the Meeting ) of shareholders of Oncolytics Biotech Inc. (the Corporation ) will be held at the Hilton Toronto, 145
Read more →Interim Consolidated Financial Statements Oncolytics Biotech Inc. March 31, 2012 and 2011 ONCOLYTICS BIOTECH INC. INTERM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION March 31, December 31, Notes 2012 $ 2011 $ Assets Current assets Cash and cash equivalents 3 44
Read more →210, 1167 Kensington Cr. N.W. Calgary, Alberta Canada T2N 1X7 Oncolytics Biotech Inc. Announces First Quarter 2012 Results CALGARY, AB, May 10, 2012 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and ope
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Enters into Sponsorship Agreement with NCIC CTG for Randomized Phase II Study in Colorectal Cancer CALGARY, AB, --- May 3, 2012 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has ente
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. to Present at 11th Annual Needham Healthcare Conference CALGARY, AB, April 4, 2012 --- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Completes Enrollment in First Stage of Phase III Study in Head and Neck Cancers CALGARY, AB, --- April 2, 2012 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has completed enrollment
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting CALGARY, AB, --- March 29, 2012 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that abstracts of preclinical research on reo
Read more →210, 1167 Kensington Cr. N.W. Calgary, Alberta Canada T2N 1X7 Oncolytics Biotech Inc. Announces 2011 Year End Results CALGARY, AB, March 15th, 2012 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and oper
Read more →Consolidated Financial Statements Oncolytics Biotech Inc. December 31, 2011 and 2010 STATEMENT OF MANAGEMENT'S RESPONSIBILITY Management is responsible for the preparation and presentation of the consolidated financial statements, Management's Discussion and Analysis ("MD&A")
Read more →MANAGEMENT DISCUSSION & ANALYSIS ONCOLYTICS BIOTECH INC. MANAGEMENT DISCUSSION & ANALYSIS Basis of Presentation and Transition to IFRS 1 Forward-Looking Statements 1 REOLYSIN 1 Clinical Trial Program 2 Manufacturing and Process Development 4 Intellectual Property 4 Collaborati
Read more →Oncolytics Biotech Inc. to Present at Cowen and Company 32nd Annual Health Care Conference CALGARY, AB, March 2, 2012 --- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the Cowen and C
Read more →210, 1167 Kensington Cr. N.W. Oncolytics Biotech Inc. Enters into Sponsorship Agreement with NCIC CTG for Randomized Phase II Study in Prostate Cancer CALGARY, AB, --- February 21, 2012 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has
Read more →Oncolytics Biotech Inc. Closes Bought Deal Financing for Total Gross Proceeds of Cdn$21.3 Million CALGARY, AB - February 8, 2012 - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC, NASDAQ:ONCY) today announced that it has closed its previously announced Cdn$18.5
Read more →Oncolytics Biotech Inc. Announces Increase in Size of Bought Deal Financing to Cdn$18.5 Million CALGARY, AB - January 24, 2012 - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC, NASDAQ:ONCY) today announced an increase in the size of the bought deal financing an
Read more →210, 1167 Kensington Cr. N.W. [FOR IMMEDIATE RELEASE Oncolytics Biotech Inc. Announces Phase 2 Clinical Trial of REOLYSIN in Combination with Gemcitabine in Pancreatic Cancer Reaches Primary Endpoint CALGARY, AB, December 2, 2011 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ON
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Announces Start of Conformity Testing with SAFC CALGARY, AB, November 21, 2011 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced that SAFC, a Division of Sigma-Aldrich Corporat
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Collaborators to Present Positive Phase 2 REOLYSIN Clinical Data in Pancreatic Cancer at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference CALGARY, AB, November 14, 2011 --- Oncolytics Biotech Inc. (TSX:
Read more →CERTIFICATION OF INTERIM FILINGS I, Brad Thompson, President and CEO of Oncolytics Biotech Inc., certify the following: Date: November 9, 2011 /s/ Brad Thompson Brad Thompson, PhD President and CEO CERTIFICATION OF INTERIM FILINGS I, Doug Ball, CFO of Oncolytics Biotec
Read more →Third Quarter Report Oncolytics Biotech Inc. Oncolytics Q3 2011 Message to Shareholders We achieved a number of important milestones during the third quarter of 2011. We expanded enrollment in our Phase III head and neck cancer trial, reported positive interim results in our P
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. to Host Conference Call to Discuss Clinical Data Being Presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference CALGARY, AB, November 11, 2011 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("O
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. to Present at the JMP Securities Healthcare Conference CALGARY, AB, September 22, 2011 --- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Com
Read more →CERTIFICATION OF INTERIM FILINGS I, Brad Thompson, President and CEO of Oncolytics Biotech Inc., certify the following: /s/ Brad Thompson Brad Thompson, PhD President and CEO CERTIFICATION OF INTERIM FILINGS I, Doug Ball, CFO of Oncolytics Biotech Inc., certify the foll
Read more →Oncolytics Message to Shareholders In an effort to maximize the future commercial potential of REOLYSIN , we continue to build upon and progress through our REOLYSIN research and development program. In the second quarter of 2011, we focused on the expansion of our Phase III cli
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Collaborators Present Positive REOLYSIN Clinical Trial Results at the 14th World Conference on Lung Cancer CALGARY, AB, July 6, 2011 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics") today announced that a pr
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at the 14th World Conference on Lung Cancer CALGARY, AB, June 8, 2011 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics") today announced that an abstract covering inte
Read more →ONCOLYTICS BIOTECH INC. Annual General Meeting Held on May 11, 2011 REPORT OF VOTING RESULTS Pursuant to Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations Matter Voted Upon Outcome of Vote 1. Fixing the number of directors of the issuer for the
Read more →CERTIFICATION OF INTERIM FILINGS I, Brad Thompson, President and CEO of Oncolytics Biotech Inc., certify the following: /s/ Brad Thompson Brad Thompson, PhD President and CEO CERTIFICATION OF INTERIM FILINGS I, Doug Ball, CFO of Oncolytics Biotech Inc., certify the foll
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. to Present at Jeffries 2011 Global Healthcare Conference CALGARY, AB, June 2, 2011 --- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Reports Correction to First Quarter 2011 Results Press Release CALGARY, AB, May 12, 2011 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") reports a correction of a formatting error in its fir
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Announces Phase I Multiple Myeloma Cancer Study CALGARY, AB, --- May 10, 2011 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Cancer Therapy Evaluation Program, Division of Cancer Trea
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Announces Details of 2011 Annual Shareholder Meeting CALGARY, AB, --- May 5, 2011 --- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that its 2011 Annual General Meeting of the Shareholders will be held on W
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Announces Positive Data from Translational Clinical Trial Investigating REOLYSIN in Patients with Metastatic Colorectal Cancer CALGARY, AB, --- April 20, 2011 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) to
Read more →SW, 6th floor Date: February 25, 2011 Calgary AB, T2P 3S8 www.computershare.com Securities Regulatory Authorities Subject: ONCOLYTICS BIOTECH INC. We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual
Read more →Table of Contents technology changing life Table of Contents Oncolytics Biotech Inc. is focused on the development of oncolytic viruses as a novel and effective approach to cancer treatment. Oncolytics clinical program includes a variety of human trials including a Phase III
Read more →NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO THE SHAREHOLDERS OF ONCOLYTICS BIOTECH INC. NOTICE IS HEREBY GIVEN that the annual general meeting (the Meeting ) of shareholders of Oncolytics Biotech Inc. (the Corporation ) will be held at the Hilton Toronto, 145 Richmond
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. to Present at 10th Annual Needham Healthcare Conference CALGARY, AB, March 31, 2011 --- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Compan
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Completes Patient Enrollment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN in Combination with Paclitaxel and Carboplatin in Head and Neck Cancers CALGARY, AB, --- March 24, 2011 - Oncolytics Biotech Inc. ("Oncolytics
Read more →Consolidated Financial Statements Oncolytics Biotech Inc. December 31, 2010 and 2009 STATEMENT OF MANAGEMENT'S RESPONSIBILITY Management is responsible for the preparation and presentation of the consolidated financial statements, Management's Discussion and Analysis ("MD&A")
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Announces 2010 Year End Results CALGARY, AB, March 17, 2011 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the year ende
Read more →MANAGEMENT DISCUSSION & ANALYSIS FORWARD-LOOKING STATEMENTS REOLYSIN DEVELOPMENT UPDATE FOR 2010 Clinical Trial Program Clinical Trial - Program Expansion Clinical Trial - 2010 Results Pre-Clinical and Collaborative Program Manufacturing and Process Development Intellectu
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. to Present at 31st Annual Cowen and Company Healthcare Conference CALGARY, AB, March 3, 2011 --- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of t
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Receives $7.7 Million from Exercise of Warrants CALGARY, AB - March 1, 2011 - Oncolytics Biotech Inc. ("Oncolytics" or the "Corporation") (TSX:ONC; NASDAQ:ONCY) today announced that the Corporation's biggest institutional sha
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. to Present at RBC Capital Markets Healthcare Conference CALGARY, AB, February 24, 2011 --- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in a panel discussion at th
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Announces Start of Enrollment in Randomized Phase II Pancreatic Cancer Study CALGARY, AB, --- February 16, 2011 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that enrollment has begun in a 2-
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Meets Primary Endpoint for First Part of U.S. Phase 2 Pancreatic Cancer Clinical Trial CALGARY, AB, --- February 14, 2011 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced preliminary results fro
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. to Present at 13th Annual BIO CEO & Investor Conference CALGARY, AB, February 10, 2011 --- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Com
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Receives US$6.8 Million from Exercise of Warrants CALGARY, AB - January 25, 2011 - Oncolytics Biotech Inc. ("Oncolytics" or the "Corporation") (TSX:ONC; NASDAQ:ONCY) today announced that pursuant to the acceleration of the ex
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Announces 2-Arm, Randomized Phase II Pancreatic Cancer Study CALGARY, AB, --- January 18, 2011 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Cancer Therapy Evaluation Program, Divisi
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Announces Opening of Enrollment in U.S. Phase I Colorectal Cancer Study CALGARY, AB, --- January 10, 2011 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that a U.S. Phase I study of REOLYSIN i
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Accelerates Warrant Expiry Date CALGARY, AB - December 23, 2010 - Oncolytics Biotech Inc. ("Oncolytics" or the "Corporation") (TSX:ONC; NASDAQ:ONCY) today announced, that in accordance with the terms of the warrant indenture
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Announces Start of Enrollment in Randomized Phase II Ovarian Cancer Study CALGARY, AB, --- December 1, 2010 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today the start of enrollment in a randomi
Read more →Oncolytics Biotech Inc. Announces Publication of Phase I Clinical Trial Results Examining Combination of REOLYSIN and Docetaxel in Clinical Cancer Research CALGARY, AB, --- November 29, 2010 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that a p
Read more →CERTIFICATION OF INTERIM FILINGS I, Brad Thompson, President and CEO of Oncolytics Biotech Inc., certify the following: Date: November 9, 2010 CERTIFICATION OF INTERIM FILINGS I, Doug Ball, CFO of Oncolytics Biotech Inc., certify the following: Date: November 9, 2010
Read more →Third Quarter Report Oncolytics Biotech Inc. Oncolytics' Q3 2010 Message to Shareholders In the third quarter, we continued to support a broad range of activities critical to moving REOLYSIN towards becoming an approved cancer therapeutic. To this end, our focus is on moving f
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Announces Third Quarter 2010 Results CALGARY, AB, November 10, 2010 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the q
Read more →210, 1167 Kensington Cr. N.W Calgary, Alberta Canada T2N 1X7 Oncolytics Biotech Inc. Closes Cdn$28.77 Million Bought Deal Financing CALGARY, AB November 8, 2010 Oncolytics Biotech Inc. ( Oncolytics or the Company ) (TSX:ONC, NASDAQ:ONCY) today announced that it has closed
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at the EORTC-NCI-AACR Meeting CALGARY, AB, November 1, 2010 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics") today announced that an abstract covering preclinical r
Read more →Oncolytics Biotech Inc. Announces Cdn$25 Million Bought Deal Financing CALGARY, AB October 28, 2010 Oncolytics Biotech Inc. ( Oncolytics or the Company ) (TSX:ONC, NASDAQ:ONCY) today announced that it has entered into an agreement with a syndicate of underwriters (the Underwri
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Collaborators Present Data from U.K. Translational Colorectal Cancer Study at the International Symposium on CTL and Immunostimulation CALGARY, AB, --- October 26, 2010 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDA
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. to Present at BIO Investor Forum CALGARY, AB, October 4, 2010 --- Dr. Brad Thompson, President and Chief Executive Officer of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Announces Issuance of Key U.S. Patent CALGARY, AB --- September 28, 2010 - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted U.S. Patent, No. 7,803,385 entitled "Reovirus
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. to Present at Rodman & Renshaw Annual Global Investment Conference CALGARY, AB, September 9, 2010 --- Mr. Doug Ball, Chief Financial Officer of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overvi
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Announces Randomized Phase II Ovarian Cancer Study to be Conducted by the Gynecologic Oncology Group and Sponsored by the National Cancer Institute CALGARY, AB, --- September 2, 2010 - Oncolytics Biotech Inc. ("Oncolytics") (
Read more →First Quarter Report Oncolytics Biotech Inc. Second Quarter Report For the quarter ended June 30, 2010 In the second quarter of 2010 we reached a number of key clinical milestones, most notably the opening of enrollment in our Phase 3 clinical study examining REOLYSIN in comb
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Receives No Objection Letter from Health Canada to Conduct Phase 3 Trial of REOLYSIN in Head and Neck Cancers CALGARY, AB, --- July 19, 2010 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Announces Issuance of 35th U.S. Patent CALGARY, AB --- June 17, 2010 - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted its 35th U.S. Patent, No. 7,731,951 entitled "Vir
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Collaborators Present Positive Updated U.K. Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the ASCO Annual Meeting CALGARY, AB, --- June 7, 2010 - Oncolytics Biotech Inc. ("Oncolytics"
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. To Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting CALGARY, AB, --- June 4, 2010 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONC
Read more →ONCOLYTICS BIOTECH INC. Annual and Special Meeting Held on May 11, 2010 REPORT OF VOTING RESULTS Pursuant to Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations Matter Voted Upon Outcome of Vote 1. Fixing the number of directors of the issuer for
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN in Head and Neck Cancers CALGARY, AB, --- June 1, 2010 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has rec
Read more →Oncolytics Biotech Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial CALGARY, AB, --- May 26, 2010 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Cancer Therapy & Research Center at the University of Tex
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN in Head and Neck Cancers CALGARY, AB, --- May 25, 2010 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has opened enrollmen
Read more →Oncolytics Biotech Inc. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 11. RECONCILIATION OF CANADIAN GAAP TO U.S. GAAP Our consolidated financial statements are prepared in accordance with Canadian GAAP which, in most respects, conforms to U.S. GAAP. Significant differences betwe
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Announces Phase I Colorectal Cancer Study CALGARY, AB, --- May 19, 2010 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that following submission to the U.S. Food and Drug Administration (FDA)
Read more →First Quarter Report Oncolytics Biotech Inc. 2010 FIRST QUARTER REPORT For the quarter ended March 31, 2010 The last three months have been eventful ones for Oncolytics as we expanded our evolving clinical program and reported new clinical and preclinical data. Expanding Cli
Read more →CERTIFICATION OF INTERIM FILINGS I, Brad Thompson, President and CEO of Oncolytics Biotech Inc., certify the following: WSLegal\052277\00014\5218666v1 CERTIFICATION OF INTERIM FILINGS I, Doug Ball, CFO of Oncolytics Biotech Inc., certify the following: WSLegal\052277\00014\5
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Announces First Quarter 2010 Results CALGARY, AB, May 12, 2010 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the quarte
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Announces Details of 2010 Annual Shareholder Meeting CALGARY, AB, --- May 7, 2010 --- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that its 2010 Annual and Special Meeting of the Shareholders will be held
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial CALGARY, AB, --- April 23, 2010 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today tha
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting CALGARY, AB, --- April 14, 2010 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that abstracts covering both clinical and prec
Read more →Subject: ONCOLYTICS BIOTECH INC. We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual Special Meeting Record Date for Notice of Meeting : 26/03/2010 Record Date for Voting (if applicable) : 26/03/2
Read more →technology changing life Biotech Inc. is focused on the development of oncolytic viruses as a novel and effective approach to cancer treatment. Oncolytics clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN , i
Read more →NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TO THE SHAREHOLDERS OF ONCOLYTICS BIOTECH INC. NOTICE IS HEREBY GIVEN that the annual and special meeting (the Meeting ) of shareholders of Oncolytics Biotech Inc. (the Corporation ) will be held at the Hilton Toronto, 145 R
Read more →Oncolytics Biotech Inc. Announces Publication of Preclinical Research on Combination of Antiangiogenic Cancer Therapy with Oncolytic Virotherapy CALGARY, AB, --- April 8, 2010 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that a paper entitled "
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. to Present at BioFinance 2010 CALGARY, AB, --- April 6, 2010 --- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), is scheduled to present a corporate overview of the Company at BioFina
Read more →Oncolytics Biotech Inc. Announces Start of Enrolment in U.S. Phase 2 SCC Lung Cancer Trial CALGARY, AB, --- March 30, 2010 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Cancer Therapy & Research Center at the University of Texas Health
Read more →Announces 2009 Year End Results CALGARY, AB, March 9, 2010 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the year ended December 31, 2009. we executed on our business pl
Read more →Biotech Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN in Head and Neck Cancers to Host Clinical Update Conference Call-- CALGARY, AB, --- February 16, 2010 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that
Read more →Inc. to Present at 12th Annual BIO CEO & Investor Conference CALGARY, AB, February 4, 2010 --- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the Annual BIO CEO & Investor Conferen
Read more →to Present at BioPartnering North America CALGARY, AB, --- January 21, 2010 --- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the Annual BioPartnering North America (BPN) Conferenc
Read more →Biotech Inc. Appoints Senior Vice President, Global Licensing and Business Development CALGARY, AB, December 11, 2009 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced the appointment of Dr. Alan Warrander to the role of Senio
Read more →Biotech Inc. Announces Exercise of Underwriters' Over-Allotment Option CALGARY, AB - December 2, 2009 - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ:ONCY) announced today that in connection with its previously announced unit offering, the underwri
Read more →US$12.75 Million Unit Offering CALGARY, AB - November 23, 2009 - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ:ONCY) announced today that it has closed its previously announced US$12,750,000 offering in which a syndicate of underwriters purchased 4
Read more →ONCOLYTICS BIOTECH INC. UNDERWRITING AGREEMENT Oppenheimer Co. Inc. as Representative of the several Underwriters named in Schedule I hereto c/o Oppenheimer Co. Inc. New York, New York 10017 Ladies and Gentlemen: Oncolytics Biotech Inc., an Alberta corporation (the Compan
Read more →Biotech Inc. Announces Terms of Unit Offering CALGARY, AB - November 18, 2009 - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ:ONCY) announced today that it has entered into an underwriting agreement for an offering of 4,250,000 units, each comprise
Read more →Collaborators to Present Updated Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC CALGARY, AB, November 16, 2009 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced that a
Read more →TO CONSOLIDATED FINANCIAL STATEMENTS 30, 2009 (unaudited) OF CANADIAN GAAP TO US GAAP consolidated financial statements of the Company are prepared in accordance with Canadian GAAP, which, in most respects, conforms to US GAAP. In preparing these interim statements the Compa
Read more →Thompson, President and CEO of Oncolytics Biotech Inc., certify the WSLegal\052277\00014\5218666v1 Ball, CFO of Oncolytics Biotech Inc., certify the following: WSLegal\052277\00014\5218666v1
Read more →the quarter ended September 30, 2009 to a Late-Stage Clinical Program to quarter end we took a major step forward by reaching an agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for the design of a Phase III trial
Read more →Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual CALGARY, AB, November 6, 2009 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced updated results from a Phase II study of intravenous patients with sar
Read more →Biotech Inc. Announces Results of Second Warrant Expiry Date Acceleration Program CALGARY, AB - November 3, 2009 - Oncolytics Biotech Inc. ("Oncolytics" or the "Corporation") (TSX:ONC; NASDAQ:ONCY) announces, that pursuant to the accelerated expiry of those warrants issued o
Read more →Collaborators to Present Phase II Sarcoma Trial Results at CTOS Annual CALGARY, AB, October 30, 2009 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") announced that a poster presentation covering updated results of a Phase II study of REOLYSI
Read more →Biotech Inc. Announces Issuance of 33rd U.S. CALGARY, AB --- October 27, 2009 - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted its 33rd U.S. Patent, No. 7,608,257, entitled "Sensitization of Chemotherapeutic Agent Res
Read more →Biotech Inc. Announces Results of First Warrant Expiry Date Acceleration Program CALGARY, AB - October 26, 2009 - Oncolytics Biotech Inc. ("Oncolytics" or the "Corporation") (TSX:ONC; NASDAQ:ONCY) announces, that pursuant to the provision of written notification on September
Read more →Biotech Inc. to Present at BIO Investor Forum 2009 CALGARY, AB, October 23, 2009 --- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the Annual BIO Investor Forum 2009 on Wednesday,
Read more →Biotech Inc. Announces Investment in Private Biotechnology Company CALGARY, AB --- October 20, 2009 - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") announced today that it has made an investment in British Canadian Biosciences Corp. (BCBC), a privately held
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. to Present at BioPartnering Europe CALGARY, AB, October 7, 2009 --- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 17th Annual
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Accelerates Warrant Expiry Date CALGARY, AB - October 2, 2009 - Oncolytics Biotech Inc. ("Oncolytics" or the "Corporation") (TSX:ONC; NASDAQ:ONCY) announces that in accordance with the terms of the warrant indenture for those
Read more →Oncolytics Biotech Inc. Announces Phase 3 Update CALGARY, AB, --- October 1, 2009 - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY), will host a conference call and webcast on Friday, October 2, 2009 at 6:30 a.m. MT (8:30
Read more →Oncolytics Biotech Inc. Announces Start of Enrolment in U.S. Phase 2 Melanoma Cancer Clinical Trial CALGARY, AB, --- September 24, 2009 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Cancer Therapy & Research Center at the University of
Read more →210, 1167 Kensington Crescent NW Oncolytics Biotech Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial CALGARY, AB, September 24, 2009 -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ( Oncolytics') reported today that research le
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. to Present at Rodman & Renshaw 11th Annual Healthcare Conference CALGARY, AB, --- September 8, 2009--- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the Rodman & Rensha
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Announces Issuance of 32nd U.S. Patent CALGARY, AB --- September 1, 2009 - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted its 32nd U.S. Patent, No. 7,582,289, entitled
Read more →CERTIFICATION OF INTERIM FILINGS I, Brad Thompson, President and CEO of Oncolytics Biotech Inc., certify the following: WSLegal\052277\00014\5218666v1 CERTIFICATION OF INTERIM FILINGS I, Doug Ball, CFO of Oncolytics Biotech Inc., certify the following: WSLegal\052277\00014\5
Read more →Second Quarter Report For the quarter ended June 30, 2009 The second quarter of 2009 was highlighted by the announcement of additional positive clinical trial results in our monotherapy and combination trials and the successful completion of two transactions that added net proc
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Announces 2009 Second Quarter Results CALGARY, AB, July 29, 2009 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results for the three and six-month periods end
Read more →210, 1167 Kensington Cr. N.W Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN CALGARY, AB, --- July 27, 2009 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that with the support of its contract manufacturer,
Read more →Oncolytics Biotech Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting CALGARY, AB, --- July 15, 2009 -Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that a poster presentation by Dr. Jacqueline Parker et al. entitled "Anti-Tumo
Read more →210, 1167 Kensington Crescent NW Oncolytics Biotech Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC CALGARY, AB, July 16 , 2009 -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ( Oncolytics') reported today that Dr. Shizuk
Read more →Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN and Paclitaxel/Carboplatin Head and Neck Cancer Trial CALGARY, AB, --- July 2, 2009 - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that patient enrolment has been completed in the Phase II compo
Read more →and Special Meeting of Holders of Biotech Inc. (the "Issuer") Instrument 51-102 - Continuous Disclosure Obligations General Business Outcome of Vote 1. The election of the following nominees as directors of the Issuer for the ensuing year or until their successors are elected
Read more →Collaborators Present Phase II Sarcoma Trial Results at ASCO Annual Meeting CALGARY, AB, --- June 1, 2009 - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced that interim results of a Phase II study of intravenous REOLYSIN in patients with sarcomas metastatic to the
Read more →Biotech Inc.'s Research Collaborators to Data on REOLYSIN Clinical Trials at ASCO Conference CALGARY, AB, --- May 14, 2009 -Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that data from three clinical trials using REOLYSIN are scheduled to be p
Read more →210, 1167 Kensington Cr. Biotech Inc. Announces 2009 First Quarter Results CALGARY, AB, May 5, 2009 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results for the three-month period ended March 31, first quar
Read more →UNDERWRITING AGREEMENT Oncolytics Biotech Inc. 210-1167 Kensington Cr. N.W. Attention: Brad Thompson Chief Executive Officer Bolder Investment Partners, Ltd. (the Underwriter ) hereby offers to purchase from Oncolytics Biotech Inc. (the Company ) up to 3,000,000 units of th
Read more →Thompson, President and CEO of Oncolytics Biotech Inc., certify the Ball, CFO of Oncolytics Biotech Inc., certify the following:
Read more →TO CONSOLIDATED FINANCIAL STATEMENTS OF CANADIAN GAAP TO US GAAP consolidated financial statements of the Company are prepared in accordance with Canadian GAAP, which, in most respects, conforms to US GAAP. In preparing these interim statements the Company has included all ad
Read more →the quarter ended March 31, 2009 first quarter, we announced updated clinical results from three combination REOLYSIN and chemotherapy trials, all of which reported clinical benefit (complete response + partial response + stable disease) in a majority of the patients treated.
Read more →Oncolytics Biotech Inc. to Present at BioFianance CALGARY, Alberta, --- April 27, 2009 - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), is scheduled to present a corporate overview of the Company at BioFinance 2009 on Wednesday, Apri
Read more →Oncolytics Biotech Inc. Announces Positive Results U.K. Phase II REOLYSIN and Radiation Combination Clinical CALGARY, AB, --- April 7, 2009 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced positive results in its U.K. Phase II clinical trial to
Read more →Biotech Inc. Completes Enrolment in REOLYSIN /Gemcitabine Trial CALGARY, AB, --- March 25, 2009 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced the completion of patient enrolment in its U.K. clinical trial to evaluate the anti-tumour effects
Read more →Biotech Inc. Collaborators Present Reovirus Research Replicating Oncolytic Virus Meeting CALGARY, AB, --- March 23, 2009 -Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) results of two preclinical studies that were presented at the Fifth International Meeting on Replicating
Read more →Oncolytics Biotech Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN and Paclitaxel/Carboplatin Trial CALGARY, AB, --- March 20, 2009 -Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced that interim clinical results from its P
Read more →OF ANNUAL AND SPECIAL MEETING SHAREHOLDERS TO BE HELD ON MAY 5, 2009 Notice of Meeting i Solicitation of Proxies 1 Appointment of Proxyholders and Revocation of Proxies 1 Signing of Proxy 1 Voting of Proxies and Exercise of Discretion by Proxyholders 2 Voting Shares and Princip
Read more →Biotech Inc. Announces Reovirus Research to be at AACR Annual Meeting CALGARY, AB, --- March 16, 2009 -Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that abstracts covering research with reovirus (REOLYSIN ) are available on the American Association for Ca
Read more →210, 1167 Kensington Cres. NW Announces Start of Enrolment in U.S. Phase 2 Clinical Trial for Non-Small Cell Lung Cancer Patients with or EGFR-Activated Tumours CALGARY, AB, --- March 12, 2009 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today t
Read more →Biotech Inc. Reports Highlights and Financial Results for 2008 CALGARY, AB, March 4, 2009 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today reported its financial results for the year ended December 31, we selected our first pivotal pro
Read more →News release via Canada NewsWire, Toronto 416-863-9350 Attention Business Editors: Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering CALGARY, Feb. 5 /CNW/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will pr
Read more →News release via Canada NewsWire, Toronto 416-863-9350 Attention Business/Medical Editors: Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer CALGARY, Jan. 27 /C
Read more →News release via Canada NewsWire, Toronto 416-863-9350 Attention Business Editors: Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent CALGARY, Jan. 13 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted
Read more →